{"gene":"SORL1","run_date":"2026-06-10T07:46:38","timeline":{"discoveries":[{"year":2005,"finding":"SorLA/LR11 directly interacts with APP in vitro and in living cells, colocalizes with APP in endosomal and Golgi compartments, and acts as a sorting receptor that redistributes APP to the Golgi, reducing processing to Aβ. Ablation of SorLA in knockout mice increases brain Aβ levels.","method":"Co-immunoprecipitation, colocalization imaging, overexpression in neurons, SorLA-knockout mouse model","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, colocalization, in vivo KO phenotype, replicated across multiple labs","pmids":["16174740"],"is_preprint":false},{"year":2006,"finding":"SorLA's cytoplasmic domain contains an acidic cluster-dileucine-like motif and a GGA-binding site that mediate Golgi-endosome transport and AP-2-dependent endocytosis. AP-1 adaptor complex is essential for SorLA transport between Golgi membranes and endosomes; SNX1 and Vps35 (retromer components) are engaged in retraction of the receptor from endosomes.","method":"Chimeric receptor constructs, AP-1 mu1-chain-deficient cells, co-immunoprecipitation, trafficking assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — mutagenesis of sorting motifs, functional rescue experiments, multiple orthogonal approaches in one study","pmids":["17646382"],"is_preprint":false},{"year":2007,"finding":"SorLA acts as a retention factor for APP in trans-Golgi compartments/TGN, preventing release into processing pathways. Proper localization depends on functional interaction with adaptors GGA and PACS-1; aberrant targeting to the recycling compartment or plasma membrane causes faulty APP trafficking and increased amyloidogenic processing.","method":"Overexpression, dominant-negative adaptor proteins, subcellular fractionation, Aβ ELISA","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple adaptor perturbation experiments, functional APP processing readout, single lab with orthogonal approaches","pmids":["17855360"],"is_preprint":false},{"year":2006,"finding":"SorLA interacts with both APP (via cytoplasmic C99 domain) and BACE1 by co-immunoprecipitation, and reduces BACE-APP interactions in the Golgi as measured by FRET. Both full-length SorLA and a sorLA tail construct inhibited BACE-dependent APP cleavage, reducing secreted Aβ.","method":"Co-immunoprecipitation, FRET assay, APP-shedding assay, BACE overexpression","journal":"The Journal of neuroscience : the official journal of the Society for Neuroscience","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — FRET, Co-IP, and functional cleavage assay; multiple orthogonal methods in single study","pmids":["16407538"],"is_preprint":false},{"year":2006,"finding":"The binding site between SorLA and APP was mapped to the cluster of complement-type repeats (CR-cluster) in SorLA and the carbohydrate-linked domain of APP, forming a 1:1 stoichiometric complex, as determined by surface plasmon resonance and analytical ultracentrifugation of recombinant fragments.","method":"FRET assay, surface plasmon resonance, analytical ultracentrifugation of recombinant fragments","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstitution with recombinant fragments, multiple biophysical methods (SPR + ultracentrifugation + FRET), single lab","pmids":["16489755"],"is_preprint":false},{"year":2007,"finding":"SORL1 directs trafficking of APP into recycling endosomal pathways; when SORL1 is underexpressed, APP is sorted into Aβ-generating compartments. Inherited SORL1 variants occur in intronic clusters that may regulate tissue-specific SORL1 expression.","method":"siRNA knockdown of SORL1, APP trafficking assay, genetic association study","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function with defined cellular phenotype (APP mis-sorting), replicated in multiple populations","pmids":["17220890"],"is_preprint":false},{"year":2001,"finding":"SorLA is synthesized as a proreceptor cleaved by furin in late Golgi compartments, activating the Vps10p domain for ligand binding. Following activation, SorLA binds neuropeptides, receptor-associated protein, ApoE, and lipoprotein lipase, and mediates endocytosis; ~10% of full-length SorLA is expressed at the cell surface while the major pool resides in late Golgi.","method":"Furin cleavage assay, ligand binding assays, cell surface expression quantification, endocytosis assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — in vitro furin cleavage, multiple ligand binding assays, functional endocytosis readout","pmids":["11294867"],"is_preprint":false},{"year":2002,"finding":"The SorLA cytoplasmic tail binds adaptor proteins GGA1 and GGA2 via three critical C-terminal residues conforming to a novel motif (ψ-ψ-X-X-φ), distinct from the acidic cluster-dileucine motifs used by sortilin and mannose-6-phosphate receptors.","method":"Co-immunoprecipitation, mutagenesis of cytoplasmic tail residues","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with mutagenesis to define critical residues, single lab","pmids":["11821067"],"is_preprint":false},{"year":2012,"finding":"SorLA contains a FANSHY sequence in its cytoplasmic domain recognized by the VPS26 subunit of the retromer complex. Mutations in the VPS26 binding site redistribute SorLA to endosomes (away from TGN) without affecting APP binding, but cause APP mis-sorting into a non-Golgi compartment with increased amyloidogenic processing.","method":"Mutagenesis of FANSHY motif, VPS26 knockdown, subcellular fractionation, Aβ ELISA, co-immunoprecipitation","journal":"The Journal of neuroscience : the official journal of the Society for Neuroscience","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — site-directed mutagenesis of sorting motif, functional rescue, multiple orthogonal methods, single lab","pmids":["22279231"],"is_preprint":false},{"year":2014,"finding":"The VPS10P domain of SORLA binds nascent Aβ peptides and directs them to lysosomes for degradation. A familial AD mutation in SORL1 impairs this Aβ binding. SORLA overexpression in mice decreases brain Aβ levels via lysosomal targeting.","method":"Binding assay with recombinant VPS10P domain, SORLA-overexpressing mouse model, lysosomal targeting assay, site-directed mutagenesis","journal":"Science translational medicine","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — in vitro binding, transgenic mouse model, mutagenesis of binding domain, multiple orthogonal methods","pmids":["24523320"],"is_preprint":false},{"year":2010,"finding":"ROCK2 (Rho-associated coiled-coil containing protein kinase 2) binds LR11/SorLA and phosphorylates it at serine 2206 in the cytoplasmic tail. ROCK2 inhibition reduces LR11 phosphorylation and ectodomain shedding while increasing intracellular LR11 levels. Phosphorylation at S2206 is required for LR11-mediated reduction of Aβ.","method":"32P-labeling, LC-MS/MS identification of ROCK2 as binding partner, co-immunoprecipitation from human brain, ROCK inhibitor treatment, siRNA knockdown of ROCK2, S2206A mutagenesis, in vitro kinase assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — mass spectrometry identification, in vitro phosphorylation assay, site-directed mutagenesis, Co-IP from human brain; multiple orthogonal methods","pmids":["21147781"],"is_preprint":false},{"year":2013,"finding":"SorLA acts as a sorting receptor for the GDNF/GFRα1 complex, directing it from the cell surface to endosomes and then to lysosomes for GDNF degradation while GFRα1 recycles, creating a GDNF clearance pathway. SorLA also targets RET for endocytosis but not degradation. SorLA-deficient mice display elevated GDNF levels, altered dopaminergic function, hyperactivity, and reduced anxiety.","method":"SorLA-deficient mouse model, co-immunoprecipitation, endocytosis/degradation assays, behavioral phenotyping","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — KO mouse phenotype, Co-IP, and functional sorting assays; multiple readouts and replicated phenotypes","pmids":["23333276"],"is_preprint":false},{"year":2011,"finding":"SorLA regulates intracellular trafficking of lipoprotein lipase (LPL) by binding LPL under neutral and acidic conditions. SorLA expression redistributes LPL to endosomes and routes it to lysosomes for degradation, resulting in ~80% reduction of LPL activity in expressing cells.","method":"Co-immunoprecipitation, subcellular fractionation, LPL activity assay, immunofluorescence colocalization in primary neurons","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — binding confirmed by Co-IP, functional enzyme activity assay, single lab with two orthogonal methods","pmids":["21385844"],"is_preprint":false},{"year":2010,"finding":"SORLA is expressed in epithelial cells of the thick ascending limb (TAL) of Henle's loop and functionally interacts with SPAK (Ste-20-related proline-alanine-rich kinase). SORLA deficiency causes missorting of SPAK, inability to phosphorylate NKCC2 cotransporter, and inability to reabsorb sodium and chloride during osmotic stress.","method":"SORLA-deficient mouse model, immunolocalization, co-immunoprecipitation of SORLA and SPAK, NKCC2 phosphorylation assays, renal ion transport measurements","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — KO mouse with defined physiological phenotype, Co-IP, phosphorylation assay; multiple orthogonal methods","pmids":["20385770"],"is_preprint":false},{"year":2013,"finding":"SORLA is a sorting factor for the BDNF receptor TrkB, facilitating trafficking of TrkB between synaptic plasma membranes, post-synaptic densities, and cell soma. Loss of SORLA impairs neuritic transport of TrkB and blunts BDNF response in primary neurons; SORLA deficiency aggravates neuromotoric deficits in a Huntington's disease mouse model.","method":"SORLA KO neurons, live-cell imaging of TrkB trafficking, BDNF signaling assays, Huntington's disease mouse model cross","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with defined trafficking and signaling phenotype, in vivo model; single lab","pmids":["23977241"],"is_preprint":false},{"year":2016,"finding":"SORLA acts as a sorting factor for the insulin receptor (IR) in adipocytes, redirecting internalized IR from endosomes to the plasma membrane, thereby enhancing IR surface expression and strengthening insulin signal reception. Gene-dosage effects link SORLA expression to obesity and glucose tolerance in mouse models and human subjects.","method":"Mouse models with genetic loss or adipose-specific overexpression of SORLA, insulin receptor trafficking assay, co-immunoprecipitation, lipolysis assays","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple mouse models (KO and tissue-specific OE), receptor trafficking assay, Co-IP, functional metabolic readouts","pmids":["27322061"],"is_preprint":false},{"year":2015,"finding":"Soluble LR11/SorLA (sLR11) suppresses thermogenesis in adipose tissue in a cell-autonomous manner via the BMP/TGFβ signaling pathway, reducing Smad phosphorylation. LR11-deficient mice are protected from diet-induced obesity with increased browning of white adipose tissue.","method":"LR11-KO mouse model, treatment of adipocytes with sLR11, Smad phosphorylation assay, metabolic phenotyping","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Moderate — KO mouse phenotype with mechanistic pathway (Smad phosphorylation assay), cell-autonomous rescue with purified sLR11; multiple orthogonal methods","pmids":["26584636"],"is_preprint":false},{"year":2006,"finding":"After TACE-mediated ectodomain shedding of SorLA, the remaining C-terminal membrane fragment is processed by γ-secretase, releasing the SorLA cytoplasmic domain and a SorLA β-peptide. The released cytoplasmic domain translocates to the nucleus (dependent on an intact NLS) and acts as a transcriptional activator in reporter gene assays.","method":"γ-secretase inhibitors, dominant-negative presenilin mutants, presenilin knockout cells, in vitro γ-secretase assay, EGFP fusion reporter, nuclear translocation imaging, reporter gene assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — in vitro cleavage assay, genetic presenilin KO validation, NLS mutagenesis, reporter gene assay; multiple orthogonal methods","pmids":["16531402"],"is_preprint":false},{"year":2000,"finding":"SorLA binds the neuropeptide head activator (HA) at the cell surface; HA stimulates metalloprotease-mediated ectodomain shedding of SorLA, translocation of SorLA from internal membranes to the cell surface, and enhanced SorLA synthesis. Blockade of SorLA shedding or antisense oligonucleotides against SorLA decreases HA-induced cell proliferation.","method":"HA-Sepharose pulldown, metalloprotease inhibitor treatment, SorLA antisense oligonucleotides, cell proliferation assay, immunostaining of SorLA subcellular localization","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — affinity pulldown, pharmacological inhibition, antisense knockdown with functional readout; single lab","pmids":["11082041"],"is_preprint":false},{"year":2001,"finding":"LR11 overexpressed in hamster cells binds ApoE-rich lipoproteins (β-VLDL) with high affinity (similar to LDLR and VLDLR), internalizes and degrades bound β-VLDL, and promotes accumulation of cholesteryl esters and lipid droplets. RAP and β-VLDL compete for binding.","method":"Binding and internalization assays in LR11-transfected cells, cholesteryl ester assay, lipid droplet staining, competition assays with RAP","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional binding, internalization, and degradation assays with transfected cells; single lab, multiple assays","pmids":["11557679"],"is_preprint":false},{"year":2004,"finding":"LR11 forms complexes with urokinase-type plasminogen activator receptor (uPAR) on the cell surface and inhibits LRP-mediated internalization of uPAR, resulting in increased uPAR surface localization. Both cell-anchored and secreted soluble LR11 bind uPAR. In smooth muscle cells, LR11 mediates enhanced migration through upregulation of surface uPAR levels. Neutralization of LR11 reduces cuff-induced intimal thickness in mice.","method":"Co-immunoprecipitation, uPAR internalization assay, migration assay, anti-LR11 antibody neutralization in vivo","journal":"Circulation research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, functional migration assay, in vivo neutralization; single lab with multiple methods","pmids":["14764453"],"is_preprint":false},{"year":2004,"finding":"SorLA/LR11 binds components of the plasminogen-activating system (uPA, PAI-1, uPAR) and PDGF-BB similarly to LRP1, but mediates much slower internalization of bound ligand than LRP1. SorLA is substantially less efficient as a clearance receptor than LRP1, and can divert ligands from LRP1-mediated clearance.","method":"Binding assays in LRP1-deficient cells transfected with sorLA, ligand internalization rate measurements, competition assays","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — quantitative internalization assays in isogenic LRP1-deficient cells, binding comparison; single lab","pmids":["15053742"],"is_preprint":false},{"year":2012,"finding":"GGA1 specifically regulates LR11 endocytic trafficking; mutagenesis of the GGA-binding (DXXLL-like) motif in LR11 alters its endosomal distribution and its effects on APP trafficking and Aβ production. siRNA knockdown of GGA1 (but not GGA2 or GGA3) is necessary for both LR11 and BACE1 modulation of APP processing. BACE1-S498A mutation enhances BACE1 targeting to LR11-positive compartments and nullifies LR11-mediated Aβ reduction.","method":"siRNA knockdown of individual GGAs, GGA-binding site mutagenesis, Aβ ELISA, APP trafficking assay, BACE1 mutagenesis","journal":"Molecular biology of the cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — selective siRNA knockdown with functional readout, mutagenesis; single lab with multiple approaches","pmids":["22621900"],"is_preprint":false},{"year":2013,"finding":"Disruption of SORLA-PACS1 interaction (via transgenic mice expressing PACS1-binding-defective SORLA mutant) prevents SORLA/APP complexes from sorting to the TGN in neurons, increasing APP processing in the brain. Loss of PACS1 also impairs expression of cation-independent mannose-6-phosphate receptor and cathepsin B, providing a SORLA-independent mechanism for Aβ catabolism control.","method":"Transgenic mice expressing PACS1-binding mutant of SORLA, neuronal cell line knockdown, cathepsin B assay, APP processing assay","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — in vivo transgenic mouse model with specific trafficking mutation, multiple downstream readouts; single lab","pmids":["24001769"],"is_preprint":false},{"year":2015,"finding":"The SorLA CR-cluster (complement-type repeat domains) is essential for interaction with APP; deletion abolishes protection against APP processing. Mutation of fingerprint residues in CR-domains alters O-linked glycosylation of APP in the Golgi. These results identify CR-domain-mediated control of APP glycosylation as a mechanism by which SorLA protects APP from amyloidogenic processing.","method":"Stable SorLA CR-deletion and CR-mutant cell lines, co-immunoprecipitation, Aβ/sAPP ELISA, glycosylation analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — domain deletion and mutagenesis with functional readout, glycosylation assay; single lab","pmids":["25525276"],"is_preprint":false},{"year":2015,"finding":"Distinct anterograde (GGA-mediated) and retrograde (retromer-mediated) SORLA trafficking routes serve discrete functions: retromer-binding disruption causes SORLA accumulation in endosomes and enhanced APP processing, while GGA-binding disruption does not affect APP processing but causes increased brain Aβ levels attributed to a defect in anterograde lysosomal targeting of Aβ.","method":"Transgenic mice expressing GGA-binding or retromer-binding mutant SORLA, brain Aβ measurement, APP processing assays, subcellular fractionation","journal":"The Journal of neuroscience : the official journal of the Society for Neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo mouse models with specific trafficking mutations, dual pathway dissection; multiple orthogonal readouts","pmids":["26377460"],"is_preprint":false},{"year":2016,"finding":"SNX27 binds to the SORLA cytosolic tail to form a ternary complex with APP. SNX27 enhances cell surface SORLA and APP levels, and depletion of SNX27 or SORLA reduces APP endosome-to-cell surface recycling kinetics. SNX27 overexpression enhances non-amyloidogenic APP cleavage products in a SORLA-dependent manner.","method":"Co-immunoprecipitation, siRNA knockdown of SNX27/SORLA, APP recycling kinetics assay, surface APP cleavage product measurement","journal":"The Journal of neuroscience : the official journal of the Society for Neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with functional trafficking assay, epistasis via double knockdown; single lab","pmids":["27466343"],"is_preprint":false},{"year":2017,"finding":"SORLA interacts with the EphA4 receptor tyrosine kinase and attenuates ephrinA1-induced EphA4 clustering and activation, limiting downstream EphA4 signaling in neurons. SORLA transgenic mice show decreased EphA4 activation and redistribution to postsynaptic densities with milder Aβ oligomer-induced deficits in LTP and memory. Active EphA4 levels in human AD brains are inversely correlated with SORLA/EphA4 association.","method":"Co-immunoprecipitation, EphA4 activation assay, SORLA transgenic mouse model, LTP and memory behavioral tests, human AD brain analysis","journal":"The Journal of experimental medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, in vivo transgenic model, functional signaling assay; single lab with multiple methods","pmids":["29114064"],"is_preprint":false},{"year":2019,"finding":"SORLA co-precipitates with HER2 in cancer cells and promotes recycling of endosomal HER2 back to the plasma membrane via Rab4-dependent pathway. Depletion of SORLA triggers HER2 targeting to late endosomal/lysosomal compartments, impairs HER2-driven signaling, reduces in vivo tumor growth, and sensitizes cells to lysosome-targeting drugs.","method":"Co-immunoprecipitation, subcellular fractionation, SORLA siRNA depletion, Rab4-dependent trafficking assay, in vivo tumor growth assay","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Moderate — Co-IP, functional in vivo tumor model, defined trafficking mechanism (Rab4-dependent), multiple orthogonal methods","pmids":["31138794"],"is_preprint":false},{"year":2020,"finding":"SORL1 depletion in hiPSC-derived neurons (but not microglia) causes early endosome enlargement and altered localization of APP in early endosomes. BACE inhibition does not rescue endosome enlargement, demonstrating that this phenotype is independent of amyloidogenic APP processing.","method":"CRISPR-Cas9 SORL1 depletion in hiPSCs, endosome size quantification by confocal microscopy, BACE inhibitor treatment, cell-type-specific comparison (neurons vs. microglia)","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — isogenic CRISPR KO, cell-type specificity demonstrated, pharmacological epistasis (BACE inhibitor) to separate mechanism; multiple orthogonal approaches","pmids":["32492427"],"is_preprint":false},{"year":2021,"finding":"SORL1 truncating mutation causes haploinsufficiency and enlarged endosomes in human neurons. Complete loss of SORL1 causes additional defects in lysosome function and autophagy. Neuronal endolysosomal dysfunction from SORL1 loss is relieved by antisense oligonucleotide-mediated reduction of APP, placing PSEN1, APP, and SORL1 in a common pathway regulating the endolysosomal system.","method":"CRISPR-Cas9 truncating mutation in hiPSCs, isogenic WT/heterozygous/homozygous null neurons, endosome/lysosome functional assays, autophagy assay, APP-targeting antisense oligonucleotides","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — isogenic CRISPR series (WT/het/null), gene-dosage effects, epistasis via ASO rescue; multiple orthogonal methods","pmids":["34133918"],"is_preprint":false},{"year":2022,"finding":"Loss of SORL1 impairs endosomal trafficking of GLUA1, TRKB, and APP in hiPSC-derived neurons, increasing lysosomal targeting and reducing recycling endosome-to-cell surface delivery. SORL1 depletion reduces synaptic activity (measured by MEA). Increased SORL1 expression enhances endosomal recycling of APP and GLUA1.","method":"Isogenic hiPSC-derived neurons with SORL1 depletion or overexpression, confocal microscopy of endosomal trafficking, cell surface recycling and lysosomal degradation assays, MEA, RNA sequencing","journal":"Cellular and molecular life sciences : CMLS","confidence":"High","confidence_rationale":"Tier 2 / Strong — isogenic CRISPR models, multiple cargo proteins tested, functional MEA readout, transcriptomic validation; multiple orthogonal methods","pmids":["35226190"],"is_preprint":false},{"year":2021,"finding":"Rare SORL1 missense variants (R332W, S577P, R654W) cause impaired maturation and trafficking of the SorLA protein, with retention in the endoplasmic reticulum and reduced delivery to the plasma membrane and endosomal system. Expression of R332W and R654W in hiPSCs is associated with increased Aβ secretion, demonstrating a loss-of-function effect.","method":"Overexpression of 70 SorLA variants in HEK293 cells, CRISPR/Cas9-modified hiPSCs expressing endogenous variants, ER retention assay, plasma membrane delivery assay, Aβ ELISA, structural analysis","journal":"Acta neuropathologica communications","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — large-scale variant screen plus endogenous-level CRISPR validation, ER retention mechanism, functional Aβ readout; multiple methods","pmids":["34922638"],"is_preprint":false},{"year":2014,"finding":"Activation of the α2A adrenergic receptor (α2AAR) signaling disrupts APP interaction with SorLA in cells and in mouse brain, reduces Golgi localization of APP, promotes APP distribution in endosomes, and increases β-secretase cleavage and Aβ generation.","method":"α2AAR genetic deficiency and pharmacological activation, APP-SorLA co-immunoprecipitation in cells and mouse brain, subcellular APP localization by immunofluorescence, Aβ ELISA","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP from brain tissue, KO and pharmacological perturbation, subcellular localization; single lab","pmids":["25404298"],"is_preprint":false},{"year":2013,"finding":"SORLA disruption of retromer binding results in SORLA accumulation in endosomes and depletion from TGN, with overall enhanced APP processing. Disruption of GGA interaction does not affect APP processing but increases brain Aβ, attributed to defect in anterograde lysosomal Aβ targeting.","method":"Mouse models expressing SORLA variants lacking retromer or GGA binding sites, brain Aβ measurement, TGN localization assay","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo mouse models with trafficking mutants; review/perspective but citing primary mouse model data","pmids":["23813966"],"is_preprint":false},{"year":2014,"finding":"LR11/SorLA mediates cellular uptake of Aβ in an ApoE-isoform-dependent manner. Co-immunoprecipitation reveals apoE4 forms a stronger complex with LR11 than apoE3 or apoE2 (apoE4>apoE3>apoE2). ApoE4 most prominently accentuates LR11-mediated cellular uptake of extracellular Aβ in a coculture assay.","method":"Co-immunoprecipitation, cellular uptake assay with FAM-labeled Aβ in coculture, LR11 overexpression","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — Co-IP and uptake assay; single lab, functional readout but limited mechanistic depth","pmids":["25482438"],"is_preprint":false},{"year":2013,"finding":"SorLA acts as an APP-sorting receptor distinct from sortilin: SorLA mainly colocalizes with APP in the soma and inhibits generation of all soluble APP products, whereas sortilin interacts with APP in neurites and promotes α-secretase cleavage. Both SorLA and sortilin bind soluble APP (sAPP) via the 6A domain and mediate its internalization to different compartments.","method":"Co-immunoprecipitation, subcellular colocalization imaging, sAPP binding/internalization assay, α-secretase cleavage assay","journal":"The Journal of neuroscience : the official journal of the Society for Neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, functional processing assays, domain mapping; single lab","pmids":["23283322"],"is_preprint":false},{"year":2015,"finding":"APP mutations in the YENPTY domain (Y682G) disrupt APP complex formation with SorLA, causing endo-lysosomal dysfunction and neuronal degeneration, and alter SorLA trafficking resulting in increased SorLA secretion.","method":"APP Y682G knock-in mouse model, co-immunoprecipitation of APP/SorLA, subcellular localization of SorLA, lysosomal function assay","journal":"Frontiers in cellular neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knock-in mouse model, Co-IP, functional endolysosomal readout; single lab","pmids":["25904844"],"is_preprint":false},{"year":2020,"finding":"Soluble SORLA (sSORLA) coprecipitates with EGF receptor (EGFR) in vitro, increases EGFR Y1173 phosphorylation, and activates ERK signaling and Fos transcription in neurons. sSORLA promotes neurite outgrowth and regeneration; pharmacological EGFR or ERK inhibition reverses these effects.","method":"Co-precipitation of sSORLA and EGFR, EGFR phosphorylation assay, ERK activation assay, pharmacological inhibitors, neurite outgrowth assay, RNAseq in SORLA transgenic mouse hippocampus","journal":"The Journal of neuroscience : the official journal of the Society for Neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-precipitation, phosphorylation assay, pharmacological epistasis, in vivo transcriptomics; single lab","pmids":["32601248"],"is_preprint":false},{"year":2017,"finding":"SorLA mediates cellular uptake of IL-6 and circulating IL-6R in astrocytes, interacts with membrane-bound IL-6R at the cell surface to downregulate IL-6 cis-signaling, and the shed SorLA ectodomain stabilizes IL-6 and facilitates its trans-signaling.","method":"Co-immunoprecipitation of SorLA and IL-6R, IL-6 and IL-6R uptake assay, IL-6 signaling assay, ectodomain shedding assay","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, functional signaling and uptake assays; single lab","pmids":["28265003"],"is_preprint":false},{"year":2016,"finding":"CLF-1 has independent binding sites for CLC, CNTFRα, and SorLA. SorLA promotes downregulation of CNTFRα pool in stimulated cells via its endocytic receptor activity, and may bind and concentrate the tripartite soluble CLC:CLF-1:CNTFRα complex on cell membranes to facilitate gp130/LIFRβ signaling.","method":"Binding assays, co-immunoprecipitation, CNTFRα turnover assay, signaling assays with CLF-1 mutants","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple binding assays, functional signaling readout, site-specific mutagenesis of binding regions; single lab","pmids":["26858303"],"is_preprint":false},{"year":2014,"finding":"Tetraspanin CD9 modulates ADAM17-mediated shedding of LR11 on leukocyte surfaces. CD9 overexpression reduces sLR11 release; anti-CD9 antibody treatment or CD9 shRNA knockdown increases sLR11 shedding, which is blocked by a metalloprotease inhibitor.","method":"CD9 overexpression and shRNA knockdown, anti-CD9 neutralizing antibodies, metalloprotease inhibitor treatment, sLR11 ELISA, confocal colocalization","journal":"Experimental & molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function for CD9 with pharmacological validation of ADAM17 dependence; single lab","pmids":["24699135"],"is_preprint":false},{"year":2006,"finding":"N-linked oligosaccharides in the VPS10p domain of SorLA/LR11 are modified with terminal β1,4-linked GalNAc-4-SO4 in kidney and brain. Two sequences with basic amino acids within the Vps10p domain mediate recognition by GalNAcTIII and GalNAcTIV transferases.","method":"Biochemical isolation of oligosaccharides, co-expression of Vps10p domain with GalNAcTIII/IV, domain mutagenesis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — biochemical glycan characterization, enzyme co-expression assay, domain mapping; single lab","pmids":["17121844"],"is_preprint":false},{"year":2023,"finding":"SORL1 loss in iPSC-derived neurons causes neuron-specific reduction in APOE and CLU protein levels and altered lipid profiles. Enhancement of retromer-mediated trafficking rescues tau phenotypes but not APOE levels. TGF-β/SMAD signaling is implicated in SORL1 function regulating APOE RNA levels in a SORL1-dependent manner.","method":"SORL1-null iPSC-derived neurons, astrocytes, microglia, endothelial cells; retromer enhancer treatment; SMAD pathway modulation; APOE/CLU protein quantification; RNA-seq","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — isogenic CRISPR KO in multiple cell types, pharmacological pathway dissection, transcriptomic validation; single lab","pmids":["37611586"],"is_preprint":false},{"year":2023,"finding":"SORLA dimerizes via its fibronectin-type-III (3Fn) and VPS10p domains within retromer-positive endosomal tubules. A SORLA fragment comprising 3Fn, transmembrane, and cytoplasmic domains forms dimers and enhances retromer-dependent APP recycling and decreases amyloidogenic processing.","method":"X-ray crystallography, AI-based structural modeling, SORLA domain fragment expression and dimerization assays, APP recycling assay, Aβ measurement","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystallographic evidence plus functional domain fragment validation; multiple orthogonal approaches","pmids":["36652482"],"is_preprint":false},{"year":2024,"finding":"The SORL1 p.Y1816C variant impairs SORLA homodimerization in the endosome, leading to decreased trafficking to the cell surface and reduced sSORLA shedding. iPSC-derived neurons with engineered p.Y1816C have enlarged endosomes. The trafficking defect can be rescued by expression of the SORLA 3Fn-minireceptor.","method":"Segregation analysis in three families, CRISPR-engineered iPSC-derived neurons, dimerization assay, cell surface trafficking assay, sSORLA shedding measurement, endosome size quantification, 3Fn-minireceptor rescue","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — isogenic CRISPR neurons, dimerization assay, functional rescue; multiple orthogonal methods","pmids":["39226352"],"is_preprint":false},{"year":2021,"finding":"SorLA forms a trimeric complex with HER2 and HER3, attenuating lysosomal degradation of the HER2-HER3 dimer in a Rab4-dependent manner. Heregulin-mediated signaling supports SorLA transcription downstream of the MAPK pathway. SorLA loss compromises heregulin-induced proliferation and sensitizes anti-HER2 therapy-resistant breast cancer cells to neratinib.","method":"Co-immunoprecipitation of SorLA/HER2/HER3, SorLA siRNA depletion, Rab4 trafficking assay, heregulin signaling assay, cancer spheroid and zebrafish xenograft models","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — trimeric complex Co-IP, in vivo zebrafish model, Rab4-dependent mechanism; single lab","pmids":["33420373"],"is_preprint":false},{"year":2022,"finding":"SORL1 haploinsufficiency in Göttingen minipigs (via CRISPR-Cas9) phenocopies the preclinical in vivo AD profile seen with APP, PSEN1, and PSEN2 mutations, resulting in elevated Aβ and tau levels preceding amyloid plaque formation.","method":"CRISPR-Cas9 gene editing in minipigs, CSF and plasma biomarker measurements (Aβ, tau)","journal":"Cell reports. Medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — large animal gene-edited model with AD-relevant biomarkers; single study","pmids":["36099918"],"is_preprint":false},{"year":2024,"finding":"The familial AD SORL1 p.R953C variant, occurring in the YWTD-domain, causes retention of SORL1 in the endoplasmic reticulum, decreased receptor maturation and shedding, and impaired endosomal trafficking.","method":"Family segregation analysis, SORL1 variant functional characterization in cell lines, ER retention assay, maturation/shedding assay, endosomal trafficking assay","journal":"Acta neuropathologica","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — variant characterization with ER retention and shedding assays; single lab, multiple complementary assays","pmids":["38244079"],"is_preprint":false},{"year":2013,"finding":"The soluble form of LR11 (sLR11) regulates hypoxia-induced, uPAR-mediated adhesion of hematopoietic stem and progenitor cells (HSPCs) to stromal cells. Hypoxia induces HIF-1α binding to the LR11 promoter, increasing LR11 expression and sLR11 production. sLR11 co-immunoprecipitates with uPAR and enhances HSPC attachment; attachment is reduced by anti-uPAR antibodies.","method":"LR11-KO mouse HSPC adhesion assay, sLR11 treatment, anti-uPAR blocking, HIF-1α knockdown, HIF-1α ChIP at LR11 promoter, co-immunoprecipitation of LR11/uPAR","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, KO mouse, HIF-1α ChIP, functional adhesion assay; single lab with multiple methods","pmids":["23486467"],"is_preprint":false}],"current_model":"SORL1/SORLA is a large multidomain type-I transmembrane sorting receptor that shuttles between the trans-Golgi network, endosomes, and the cell surface through interactions with cytosolic adaptors (GGA1/2, PACS-1, retromer via VPS26-FANSHY, AP-1, AP-2, SNX27); it binds APP via its complement-type repeat cluster and the VPS10P domain sequesters nascent Aβ for lysosomal degradation, thereby limiting amyloidogenic processing—with retromer-mediated retrograde trafficking suppressing APP processing and GGA-mediated anterograde trafficking directing Aβ to lysosomes; additionally, SORLA regulates endosomal recycling of multiple cargoes (GLUA1, TRKB, HER2, insulin receptor) and controls signaling by GDNF/GFRα1, IL-6, CLF-1:CLC:CNTFRα, and EphA4, while its shed ectodomain activates EGFR/ERK neurite outgrowth signaling, and its phosphorylation by ROCK2 at S2206 modulates ectodomain shedding; loss-of-function—whether by gene knockout, CRISPR haploinsufficiency, or missense variants causing ER retention or dimerization defects—consistently causes early endosome enlargement, increased APP processing to Aβ, and endolysosomal dysfunction in neurons."},"narrative":{"mechanistic_narrative":"SORL1/SORLA is a large multidomain type-I transmembrane sorting receptor that governs the intracellular trafficking of amyloid precursor protein (APP) and a broad set of other cargoes through the trans-Golgi network (TGN), endosomal, and cell-surface compartments, and its loss is a central driver of the endolysosomal pathology underlying Alzheimer's disease [PMID:16174740, PMID:17220890, PMID:34133918]. Synthesized as a furin-cleaved proreceptor whose VPS10P domain becomes competent for ligand binding [PMID:11294867], SORLA binds APP directly through its complement-type repeat (CR) cluster to form a 1:1 complex, retains APP in the TGN, reduces its co-residence with BACE1, and thereby suppresses amyloidogenic processing to Aβ [PMID:16407538, PMID:16489755, PMID:25525276]; its VPS10P domain additionally captures nascent Aβ and routes it to lysosomes for degradation [PMID:24523320]. SORLA's itinerary is dictated by its cytoplasmic tail, which engages distinct adaptors—GGA1/2 via a ψ-ψ-X-X-φ motif, the retromer VPS26 subunit via a FANSHY sequence, PACS-1, AP-1/AP-2, and SNX27—such that retromer-mediated retrograde transport restrains APP processing while GGA-mediated anterograde transport directs Aβ to lysosomes [PMID:17646382, PMID:11821067, PMID:22279231, PMID:24001769, PMID:26377460, PMID:27466343]. SORLA dimerizes via its 3Fn and VPS10P domains within retromer-positive endosomal tubules to promote APP recycling, and disruption of this dimerization or of receptor maturation by familial missense variants causes ER retention, reduced surface delivery, and increased Aβ [PMID:34922638, PMID:36652482, PMID:39226352, PMID:38244079]. Beyond APP, SORLA functions as a general endosomal sorting hub that controls recycling and lysosomal targeting of TrkB, GLUA1, the insulin receptor, and HER2/HER3, and modulates GDNF/GFRα1, IL-6, and EphA4 signaling, while its shed ectodomain activates EGFR/ERK-dependent neurite outgrowth [PMID:23333276, PMID:23977241, PMID:27322061, PMID:31138794, PMID:35226190, PMID:32601248]. Loss of SORLA—by knockout, CRISPR haploinsufficiency, or trafficking-defective variants—consistently produces early-endosome enlargement and endolysosomal and autophagic dysfunction in neurons, a phenotype that places APP, PSEN1, and SORL1 in a common endolysosomal pathway and that can be relieved by lowering APP [PMID:32492427, PMID:34133918, PMID:35226190]. Truncating and missense SORL1 variants are causative for familial Alzheimer's disease through these loss-of-function mechanisms [PMID:24523320, PMID:34922638, PMID:39226352, PMID:38244079].","teleology":[{"year":2001,"claim":"Establishing that SORLA is a functional endocytic receptor required showing it matures into a ligand-binding form; furin cleavage of the proreceptor was shown to activate the VPS10P domain for binding of neuropeptides, RAP, ApoE, and lipoprotein lipase.","evidence":"Furin cleavage and ligand-binding/endocytosis assays with surface-expression quantification","pmids":["11294867"],"confidence":"High","gaps":["Did not connect receptor activation to a specific physiological cargo in vivo","Cell-surface vs. Golgi pool dynamics not mechanistically resolved"]},{"year":2002,"claim":"How SORLA tail is read by the sorting machinery was unknown; the cytoplasmic tail was shown to bind GGA1/GGA2 through a novel ψ-ψ-X-X-φ motif distinct from sortilin/MPR motifs, defining a basis for Golgi-endosome routing.","evidence":"Co-IP with site-directed mutagenesis of C-terminal residues","pmids":["11821067"],"confidence":"Medium","gaps":["Functional consequence for cargo sorting not yet tested","Single-lab Co-IP without structural detail"]},{"year":2005,"claim":"The link between SORLA and APP was established by showing direct interaction and that SORLA redistributes APP to the Golgi, reducing Aβ, with brain Aβ elevated in knockout mice—establishing SORLA as an APP sorting receptor.","evidence":"Reciprocal Co-IP, colocalization, neuronal overexpression, SORLA-KO mouse","pmids":["16174740"],"confidence":"High","gaps":["Binding interface not mapped","Mechanism of Aβ reduction (retention vs. degradation) unresolved"]},{"year":2006,"claim":"The molecular basis of SORLA's protective effect was refined by mapping the APP-binding site to the CR-cluster forming a 1:1 complex, and by demonstrating that SORLA reduces BACE1-APP co-residence and BACE-dependent cleavage.","evidence":"SPR and analytical ultracentrifugation of recombinant fragments; FRET and APP-shedding assays","pmids":["16489755","16407538"],"confidence":"High","gaps":["In vivo relevance of stoichiometry not tested","Did not address adaptor-dependent trafficking"]},{"year":2006,"claim":"Whether SORLA itself is processed like other amyloid-pathway receptors was addressed by showing TACE shedding followed by γ-secretase cleavage releases a cytoplasmic domain that translocates to the nucleus and activates transcription.","evidence":"γ-secretase inhibitors, presenilin KO cells, NLS mutagenesis, reporter assays","pmids":["16531402"],"confidence":"High","gaps":["Transcriptional target genes of the released domain not identified","Physiological role of nuclear signaling unknown"]},{"year":2007,"claim":"The trafficking logic was extended by showing SORLA retains APP in the TGN dependent on GGA and PACS-1, and that SORL1 knockdown mis-sorts APP into Aβ-generating compartments, linking expression level to amyloidogenesis and to genetic risk.","evidence":"Dominant-negative adaptors, fractionation, Aβ ELISA, siRNA, genetic association","pmids":["17855360","17220890"],"confidence":"High","gaps":["Causality of intronic variants on expression not directly demonstrated","Adaptor hierarchy at distinct trafficking steps not separated"]},{"year":2007,"claim":"The adaptor repertoire controlling SORLA itinerary was defined by identifying the acidic-cluster-dileucine/GGA-binding motifs for Golgi-endosome transport and AP-2 endocytosis, with AP-1 essential for Golgi-endosome cycling and retromer (SNX1/Vps35) for endosomal retrieval.","evidence":"Chimeric receptors, AP-1 mu1-deficient cells, Co-IP, trafficking assays","pmids":["17646382"],"confidence":"High","gaps":["Quantitative flux through each route not measured","Retromer recognition sequence not yet defined"]},{"year":2012,"claim":"The retromer-recognition determinant was identified as a FANSHY sequence bound by VPS26; mutating it redistributes SORLA away from the TGN and mis-sorts APP into amyloidogenic compartments without affecting APP binding, dissociating localization from cargo binding.","evidence":"FANSHY mutagenesis, VPS26 knockdown, fractionation, Aβ ELISA, Co-IP","pmids":["22279231"],"confidence":"High","gaps":["Did not separate retrograde vs. anterograde contributions to Aβ","In vivo confirmation pending at this stage"]},{"year":2012,"claim":"Adaptor specificity for the amyloid phenotype was sharpened by showing GGA1 (not GGA2/3) selectively governs LR11 endocytic trafficking and its modulation of APP processing, with BACE1 sorting determinants also implicated.","evidence":"Selective siRNA, GGA-site and BACE1 mutagenesis, Aβ ELISA","pmids":["22621900"],"confidence":"Medium","gaps":["Single-lab study","Endogenous-level relevance not tested"]},{"year":2013,"claim":"Anterograde vs. retrograde routes were assigned distinct functions in vivo using PACS1-, retromer-, and GGA-binding mutant mice: PACS1/retromer disruption depletes TGN SORLA and enhances APP processing, while GGA disruption raises brain Aβ via failed anterograde lysosomal Aβ targeting.","evidence":"Transgenic mice with trafficking-mutant SORLA, brain Aβ and TGN localization assays","pmids":["24001769","23813966"],"confidence":"High","gaps":["Molecular machinery of anterograde Aβ lysosomal delivery incompletely defined","Contribution of SORLA-independent PACS1 effects confounds interpretation"]},{"year":2014,"claim":"A direct Aβ-clearance function was established by showing the VPS10P domain binds nascent Aβ and routes it to lysosomes; a familial AD mutation impairs this binding, and SORLA overexpression lowers brain Aβ.","evidence":"Recombinant VPS10P binding, SORLA-overexpressing mice, lysosomal targeting, mutagenesis","pmids":["24523320"],"confidence":"High","gaps":["Relative contribution of Aβ capture vs. APP retention to net Aβ lowering unquantified","Structural basis of VPS10P–Aβ binding unresolved"]},{"year":2015,"claim":"The two trafficking routes were definitively separated in vivo and the CR-cluster mechanism refined: retromer disruption enhances APP processing whereas GGA disruption raises Aβ through anterograde defects, and CR-domain integrity controls APP O-glycosylation that gates amyloidogenic processing.","evidence":"Trafficking-mutant transgenic mice; CR-deletion/mutant cell lines, glycosylation analysis, Aβ/sAPP ELISA","pmids":["26377460","25525276"],"confidence":"High","gaps":["How glycosylation alters secretase access not mechanistically detailed","Single-lab glycosylation findings"]},{"year":2016,"claim":"SORLA's role as a general recycling receptor was extended by showing SNX27 forms a ternary complex with SORLA and APP that drives APP endosome-to-surface recycling and favors non-amyloidogenic cleavage in a SORLA-dependent manner.","evidence":"Co-IP, SNX27/SORLA double knockdown, APP recycling kinetics, surface cleavage products","pmids":["27466343"],"confidence":"Medium","gaps":["Single-lab Co-IP","Structural basis of SNX27 tail recognition not defined"]},{"year":2020,"claim":"Whether SORL1 loss causes amyloid-independent organelle pathology was tested in isogenic hiPSC neurons: SORL1 depletion enlarges early endosomes and mis-localizes APP, and BACE inhibition fails to rescue endosome enlargement, demonstrating an APP-processing-independent endosomal defect that is neuron-specific.","evidence":"CRISPR SORL1 KO hiPSCs, endosome quantification, BACE inhibitor epistasis, neuron vs. microglia comparison","pmids":["32492427"],"confidence":"High","gaps":["Cargo whose mis-trafficking drives enlargement not identified here","Mechanism of neuronal specificity unexplained"]},{"year":2021,"claim":"Gene-dosage and pathway placement were established by an isogenic WT/het/null series showing haploinsufficiency enlarges endosomes while complete loss adds lysosomal and autophagy defects, all relieved by APP-lowering ASO—placing PSEN1, APP, and SORL1 in one endolysosomal pathway.","evidence":"CRISPR truncation series in hiPSC neurons, endolysosomal/autophagy assays, APP ASO rescue","pmids":["34133918"],"confidence":"High","gaps":["Why APP lowering rescues despite APP-independent endosome phenotype reported earlier remains to be reconciled","Lysosomal step affected not pinpointed"]},{"year":2021,"claim":"The loss-of-function mechanism of disease variants was defined by showing rare missense variants (R332W, S577P, R654W) impair receptor maturation and cause ER retention with increased Aβ at endogenous expression levels.","evidence":"Large variant screen in HEK293, CRISPR hiPSCs, ER retention and PM delivery assays, Aβ ELISA","pmids":["34922638"],"confidence":"High","gaps":["Structural basis of misfolding per variant not fully resolved","Whether all variants act solely via ER retention untested"]},{"year":2022,"claim":"The cargo spectrum and synaptic consequences of SORL1 loss were broadened by showing impaired endosomal trafficking of GLUA1, TRKB, and APP with reduced surface recycling and diminished synaptic activity, reversible by increased SORL1.","evidence":"Isogenic hiPSC neurons with depletion/overexpression, trafficking and recycling assays, MEA, RNA-seq","pmids":["35226190"],"confidence":"High","gaps":["Direct binding of SORLA to each cargo tail not all mapped","Link between specific cargo and synaptic deficit not isolated"]},{"year":2023,"claim":"The structural basis of SORLA function was advanced by crystallography showing dimerization via 3Fn and VPS10P domains in retromer-positive tubules, where a 3Fn-transmembrane-cytoplasmic fragment enhances retromer-dependent APP recycling and reduces Aβ.","evidence":"X-ray crystallography, AI modeling, domain-fragment dimerization and APP recycling assays","pmids":["36652482"],"confidence":"High","gaps":["Full-length receptor dimer architecture not resolved","Regulation of dimerization in cells unclear"]},{"year":2024,"claim":"Dimerization was shown to be functionally essential and disease-relevant: the familial p.Y1816C variant impairs endosomal homodimerization, reducing surface trafficking and ectodomain shedding and enlarging endosomes, with rescue by the 3Fn-minireceptor.","evidence":"Family segregation, CRISPR hiPSC neurons, dimerization/trafficking/shedding assays, minireceptor rescue","pmids":["39226352"],"confidence":"High","gaps":["Whether dimerization defect alone accounts for full neuronal phenotype untested","Therapeutic feasibility of minireceptor rescue in vivo unknown"]},{"year":2024,"claim":"An additional disease-variant mechanism was characterized by showing the familial p.R953C YWTD-domain variant causes ER retention with decreased maturation, shedding, and endosomal trafficking, reinforcing maturation defects as a recurrent loss-of-function route.","evidence":"Family segregation, ER retention, maturation/shedding, endosomal trafficking assays","pmids":["38244079"],"confidence":"Medium","gaps":["Single-lab characterization","Structural consequence within YWTD domain not resolved"]},{"year":null,"claim":"How SORLA's diverse cargo-sorting roles (APP, TrkB, GLUA1, insulin receptor, HER2/3) are coordinated, prioritized, and regulated within a single receptor remains unresolved, as does the structural basis of full-length receptor dimerization and the precise lysosomal step disrupted by complete loss.","evidence":"No single study integrates the multi-cargo sorting logic","pmids":[],"confidence":"Low","gaps":["No unified model of cargo selectivity","Full-length structure and regulated dimerization undefined","Tissue-specific cargo priorities unmapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0038024","term_label":"cargo receptor activity","supporting_discovery_ids":[0,6,9,11,15,28]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[1,8,23,26]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[3,27,39]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[6,12,19]}],"localization":[{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[0,2,3,6]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[0,1,8,29,44]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[6,18,26,32]},{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[9,11,12,30]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[17]}],"pathway":[{"term_id":"R-HSA-9609507","term_label":"Protein localization","supporting_discovery_ids":[0,1,8,25,26,31]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[1,6,28,46]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[9,30,32,45,47,48]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[11,27,38,39,46]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[30]}],"complexes":["retromer (VPS26-associated)","SORLA-APP complex","SORLA-HER2-HER3 trimeric complex"],"partners":["APP","BACE1","GGA1","VPS26","PACS1","SNX27","HER2","EPHA4"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q92673","full_name":"Sortilin-related receptor","aliases":["Low-density lipoprotein receptor relative with 11 ligand-binding repeats","LDLR relative with 11 ligand-binding repeats","LR11","SorLA-1","Sorting protein-related receptor containing LDLR class A repeats","SorLA"],"length_aa":2214,"mass_kda":248.4,"function":"Sorting receptor that directs several proteins to their correct location within the cell (Probable). Along with AP-1 complex, involved Golgi apparatus - endosome sorting (PubMed:17646382). Sorting receptor for APP, regulating its intracellular trafficking and processing into amyloidogenic-beta peptides. Retains APP in the trans-Golgi network, hence preventing its transit through late endosomes where amyloid beta peptides Abeta40 and Abeta42 are generated (PubMed:16174740, PubMed:16407538, PubMed:17855360, PubMed:24523320). May also sort newly produced amyloid-beta peptides to lysosomes for catabolism (PubMed:24523320). Does not affect APP trafficking from the endoplasmic reticulum to Golgi compartments (PubMed:17855360). Sorting receptor for the BDNF receptor NTRK2/TRKB that facilitates NTRK2 trafficking between synaptic plasma membranes, postsynaptic densities and cell soma, hence positively regulates BDNF signaling by controlling the intracellular location of its receptor (PubMed:23977241). Sorting receptor for GDNF that promotes GDNF regulated, but not constitutive secretion (PubMed:21994944). Sorting receptor for the GDNF-GFRA1 complex, directing it from the cell surface to endosomes. GDNF is then targeted to lysosomes and degraded, while its receptor GFRA1 recycles back to the cell membrane, resulting in a GDNF clearance pathway. The SORL1-GFRA1 complex further targets RET for endocytosis, but not for degradation, affecting GDNF-induced neurotrophic activities (PubMed:23333276). Sorting receptor for ERBB2/HER2. Regulates ERBB2 subcellular distribution by promoting its recycling after internalization from endosomes back to the plasma membrane, hence stimulating phosphoinositide 3-kinase (PI3K)-dependent ERBB2 signaling. In ERBB2-dependent cancer cells, promotes cell proliferation (PubMed:31138794). Sorting receptor for lipoprotein lipase LPL. Promotes LPL localization to endosomes and later to the lysosomes, leading to degradation of newly synthesized LPL (PubMed:21385844). Potential sorting receptor for APOA5, inducing APOA5 internalization to early endosomes, then to late endosomes, wherefrom a portion is sent to lysosomes and degradation, another portion is sorted to the trans-Golgi network (PubMed:18603531). Sorting receptor for the insulin receptor INSR. Promotes recycling of internalized INSR via the Golgi apparatus back to the cell surface, thereby preventing lysosomal INSR catabolism, increasing INSR cell surface expression and strengthening insulin signal reception in adipose tissue. Does not affect INSR internalization (PubMed:27322061). Plays a role in renal ion homeostasis, controlling the phospho-regulation of SLC12A1/NKCC2 by STK39/SPAK kinase and PPP3CB/calcineurin A beta phosphatase, possibly through intracellular sorting of STK39 and PPP3CB (By similarity). Stimulates, via the N-terminal ectodomain, the proliferation and migration of smooth muscle cells, possibly by increasing cell surface expression of the urokinase receptor uPAR/PLAUR. This may promote extracellular matrix proteolysis and hence facilitate cell migration (PubMed:14764453). By acting on the migration of intimal smooth muscle cells, may accelerate intimal thickening following vascular injury (PubMed:14764453). Promotes adhesion of monocytes (PubMed:23486467). Stimulates proliferation and migration of monocytes/macrophages (By similarity). Through its action on intimal smooth muscle cells and macrophages, may accelerate intimal thickening and macrophage foam cell formation in the process of atherosclerosis (By similarity). Regulates hypoxia-enhanced adhesion of hematopoietic stem and progenitor cells to the bone marrow stromal cells via a PLAUR-mediated pathway. This function is mediated by the N-terminal ectodomain (PubMed:23486467). Metabolic regulator, which functions to maintain the adequate balance between lipid storage and oxidation in response to changing environmental conditions, such as temperature and diet. The N-terminal ectodomain negatively regulates adipose tissue energy expenditure, acting through the inhibition the BMP/Smad pathway (By similarity). May regulate signaling by the heterodimeric neurotrophic cytokine CLCF1-CRLF1 bound to the CNTFR receptor by promoting the endocytosis of the tripartite complex CLCF1-CRLF1-CNTFR and lysosomal degradation (PubMed:26858303). May regulate IL6 signaling, decreasing cis signaling, possibly by interfering with IL6-binding to membrane-bound IL6R, while up-regulating trans signaling via soluble IL6R (PubMed:28265003)","subcellular_location":"Golgi apparatus membrane; Golgi apparatus, trans-Golgi network membrane; Endosome membrane; Early endosome membrane; Recycling endosome membrane; Endoplasmic reticulum membrane; Endosome, multivesicular body membrane; Cell membrane; Cytoplasmic vesicle, secretory vesicle membrane; Secreted","url":"https://www.uniprot.org/uniprotkb/Q92673/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SORL1","classification":"Not Classified","n_dependent_lines":4,"n_total_lines":1208,"dependency_fraction":0.0033112582781456954},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CANX","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/SORL1","total_profiled":1310},"omim":[{"mim_id":"608853","title":"BH3-LIKE MOTIF-CONTAINING CELL DEATH INDUCER; BLID","url":"https://www.omim.org/entry/608853"},{"mim_id":"606285","title":"SORTILIN-RELATED VPS10 DOMAIN-CONTAINING RECEPTOR 3; SORCS3","url":"https://www.omim.org/entry/606285"},{"mim_id":"606284","title":"SORTILIN-RELATED VPS10 DOMAIN-CONTAINING RECEPTOR 2; SORCS2","url":"https://www.omim.org/entry/606284"},{"mim_id":"606283","title":"SORTILIN-RELATED VPS10 DOMAIN-CONTAINING RECEPTOR 1; SORCS1","url":"https://www.omim.org/entry/606283"},{"mim_id":"602005","title":"SORTILIN-RELATED RECEPTOR; SORL1","url":"https://www.omim.org/entry/602005"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/SORL1"},"hgnc":{"alias_symbol":["gp250","LR11","LRP9","SorLA","SorLA-1"],"prev_symbol":["C11orf32"]},"alphafold":{"accession":"Q92673","domains":[{"cath_id":"-","chopping":"305-398","consensus_level":"medium","plddt":82.6364,"start":305,"end":398},{"cath_id":"-","chopping":"414-537_623-676","consensus_level":"medium","plddt":86.5904,"start":414,"end":676},{"cath_id":"3.30.60.270","chopping":"686-749","consensus_level":"medium","plddt":71.6072,"start":686,"end":749},{"cath_id":"2.120.10.30","chopping":"826-1001","consensus_level":"medium","plddt":88.2505,"start":826,"end":1001},{"cath_id":"4.10.400.10","chopping":"1204-1235","consensus_level":"medium","plddt":70.29,"start":1204,"end":1235},{"cath_id":"4.10.400","chopping":"1472-1504","consensus_level":"medium","plddt":70.5106,"start":1472,"end":1504},{"cath_id":"2.60.40.10","chopping":"1557-1648","consensus_level":"medium","plddt":67.9452,"start":1557,"end":1648},{"cath_id":"2.60.40.10","chopping":"1659-1743","consensus_level":"high","plddt":77.3444,"start":1659,"end":1743},{"cath_id":"2.60.40.10","chopping":"1848-1927","consensus_level":"high","plddt":78.6738,"start":1848,"end":1927},{"cath_id":"2.60.40.10","chopping":"1937-2022","consensus_level":"high","plddt":78.948,"start":1937,"end":2022},{"cath_id":"2.60.40.10","chopping":"2025-2138","consensus_level":"medium","plddt":66.9676,"start":2025,"end":2138},{"cath_id":"2.20.130","chopping":"1785-1843","consensus_level":"medium","plddt":75.7698,"start":1785,"end":1843}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q92673","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q92673-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q92673-F1-predicted_aligned_error_v6.png","plddt_mean":73.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SORL1","jax_strain_url":"https://www.jax.org/strain/search?query=SORL1"},"sequence":{"accession":"Q92673","fasta_url":"https://rest.uniprot.org/uniprotkb/Q92673.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q92673/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q92673"}},"corpus_meta":[{"pmid":"17220890","id":"PMC_17220890","title":"The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease.","date":"2007","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17220890","citation_count":929,"is_preprint":false},{"pmid":"16174740","id":"PMC_16174740","title":"Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein.","date":"2005","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16174740","citation_count":547,"is_preprint":false},{"pmid":"15313836","id":"PMC_15313836","title":"Loss of apolipoprotein E receptor LR11 in Alzheimer disease.","date":"2004","source":"Archives of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/15313836","citation_count":280,"is_preprint":false},{"pmid":"16452683","id":"PMC_16452683","title":"The lipoprotein receptor LR11 regulates amyloid beta production and amyloid precursor protein traffic in endosomal compartments.","date":"2006","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/16452683","citation_count":246,"is_preprint":false},{"pmid":"22279231","id":"PMC_22279231","title":"Retromer binds the FANSHY sorting motif in SorLA to regulate amyloid precursor protein sorting and processing.","date":"2012","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/22279231","citation_count":225,"is_preprint":false},{"pmid":"17646382","id":"PMC_17646382","title":"Sorting by the cytoplasmic domain of the amyloid precursor protein binding receptor SorLA.","date":"2007","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17646382","citation_count":165,"is_preprint":false},{"pmid":"17855360","id":"PMC_17855360","title":"SorLA/LR11 regulates processing of amyloid precursor protein via interaction with adaptors GGA and PACS-1.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17855360","citation_count":154,"is_preprint":false},{"pmid":"16407538","id":"PMC_16407538","title":"Interaction of the cytosolic domains of sorLA/LR11 with the amyloid precursor protein (APP) and beta-secretase beta-site APP-cleaving enzyme.","date":"2006","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/16407538","citation_count":154,"is_preprint":false},{"pmid":"11294867","id":"PMC_11294867","title":"Activation and functional characterization of the mosaic receptor SorLA/LR11.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11294867","citation_count":151,"is_preprint":false},{"pmid":"25382023","id":"PMC_25382023","title":"Coding mutations in SORL1 and Alzheimer disease.","date":"2015","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/25382023","citation_count":146,"is_preprint":false},{"pmid":"16489755","id":"PMC_16489755","title":"Molecular dissection of the interaction between amyloid precursor protein and its neuronal trafficking receptor SorLA/LR11.","date":"2006","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16489755","citation_count":141,"is_preprint":false},{"pmid":"24523320","id":"PMC_24523320","title":"Lysosomal sorting of amyloid-β by the SORLA receptor is impaired by a familial Alzheimer's disease mutation.","date":"2014","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24523320","citation_count":135,"is_preprint":false},{"pmid":"21220680","id":"PMC_21220680","title":"Meta-analysis of the association between variants in SORL1 and Alzheimer disease.","date":"2011","source":"Archives of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/21220680","citation_count":132,"is_preprint":false},{"pmid":"28789839","id":"PMC_28789839","title":"Contribution to Alzheimer's disease risk of rare variants in TREM2, SORL1, and ABCA7 in 1779 cases and 1273 controls.","date":"2017","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/28789839","citation_count":132,"is_preprint":false},{"pmid":"16957580","id":"PMC_16957580","title":"LR11/SorLA expression is reduced in sporadic Alzheimer disease but not in familial Alzheimer disease.","date":"2006","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/16957580","citation_count":130,"is_preprint":false},{"pmid":"32492427","id":"PMC_32492427","title":"Depletion of the AD Risk Gene SORL1 Selectively Impairs Neuronal Endosomal Traffic Independent of Amyloidogenic APP Processing.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/32492427","citation_count":129,"is_preprint":false},{"pmid":"19036982","id":"PMC_19036982","title":"Loss of LR11/SORLA enhances early pathology in a mouse model of amyloidosis: evidence for a proximal role in Alzheimer's disease.","date":"2008","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/19036982","citation_count":110,"is_preprint":false},{"pmid":"28537274","id":"PMC_28537274","title":"Characterization of pathogenic SORL1 genetic variants for association with Alzheimer's disease: a clinical interpretation strategy.","date":"2017","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/28537274","citation_count":109,"is_preprint":false},{"pmid":"35226190","id":"PMC_35226190","title":"The Alzheimer's gene SORL1 is a regulator of endosomal traffic and recycling in human neurons.","date":"2022","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/35226190","citation_count":103,"is_preprint":false},{"pmid":"23813966","id":"PMC_23813966","title":"Sorting receptor SORLA--a trafficking path to avoid Alzheimer disease.","date":"2013","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/23813966","citation_count":98,"is_preprint":false},{"pmid":"11821067","id":"PMC_11821067","title":"The sorLA cytoplasmic domain interacts with GGA1 and -2 and defines minimum requirements for GGA binding.","date":"2002","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/11821067","citation_count":97,"is_preprint":false},{"pmid":"26303663","id":"PMC_26303663","title":"SORL1 rare variants: a major risk factor for familial early-onset Alzheimer's disease.","date":"2015","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/26303663","citation_count":97,"is_preprint":false},{"pmid":"30911827","id":"PMC_30911827","title":"SORL1 genetic variants and Alzheimer disease risk: a literature review and meta-analysis of sequencing data.","date":"2019","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/30911827","citation_count":94,"is_preprint":false},{"pmid":"24833601","id":"PMC_24833601","title":"The Role of SORL1 in Alzheimer's Disease.","date":"2014","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/24833601","citation_count":93,"is_preprint":false},{"pmid":"23283322","id":"PMC_23283322","title":"Sortilin and SorLA display distinct roles in processing and trafficking of amyloid precursor protein.","date":"2013","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/23283322","citation_count":93,"is_preprint":false},{"pmid":"17721864","id":"PMC_17721864","title":"Neuronal LR11/sorLA expression is reduced in mild cognitive impairment.","date":"2007","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/17721864","citation_count":85,"is_preprint":false},{"pmid":"11557679","id":"PMC_11557679","title":"LR11, a mosaic LDL receptor family member, mediates the uptake of ApoE-rich lipoproteins in vitro.","date":"2001","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11557679","citation_count":81,"is_preprint":false},{"pmid":"18160637","id":"PMC_18160637","title":"Omega-3 fatty acid docosahexaenoic acid increases SorLA/LR11, a sorting protein with reduced expression in sporadic Alzheimer's disease (AD): relevance to AD prevention.","date":"2007","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/18160637","citation_count":80,"is_preprint":false},{"pmid":"19364929","id":"PMC_19364929","title":"Reduction of SorLA/LR11, a sorting protein limiting beta-amyloid production, in Alzheimer disease cerebrospinal fluid.","date":"2009","source":"Archives of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/19364929","citation_count":76,"is_preprint":false},{"pmid":"34133918","id":"PMC_34133918","title":"SORL1 deficiency in human excitatory neurons causes APP-dependent defects in the endolysosome-autophagy network.","date":"2021","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/34133918","citation_count":75,"is_preprint":false},{"pmid":"25404298","id":"PMC_25404298","title":"α(2A) adrenergic receptor promotes amyloidogenesis through disrupting APP-SorLA interaction.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/25404298","citation_count":69,"is_preprint":false},{"pmid":"10375696","id":"PMC_10375696","title":"Neuronal localization of a novel mosaic apolipoprotein E receptor, LR11, in rat and human brain.","date":"1999","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/10375696","citation_count":67,"is_preprint":false},{"pmid":"6292208","id":"PMC_6292208","title":"Transformation-dependent alterations is glycoproteins of extracellular matrix of human fibroblasts. Characterization of GP250 and the collagen-like GP140.","date":"1982","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/6292208","citation_count":66,"is_preprint":false},{"pmid":"16531402","id":"PMC_16531402","title":"SorLA signaling by regulated intramembrane proteolysis.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16531402","citation_count":64,"is_preprint":false},{"pmid":"11082041","id":"PMC_11082041","title":"Ectodomain shedding, translocation and synthesis of SorLA are stimulated by its ligand head activator.","date":"2000","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/11082041","citation_count":64,"is_preprint":false},{"pmid":"14764453","id":"PMC_14764453","title":"LR11, an LDL receptor gene family member, is a novel regulator of smooth muscle cell migration.","date":"2004","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/14764453","citation_count":63,"is_preprint":false},{"pmid":"27638701","id":"PMC_27638701","title":"Risk factor SORL1: from genetic association to functional validation in Alzheimer's disease.","date":"2016","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/27638701","citation_count":61,"is_preprint":false},{"pmid":"31138794","id":"PMC_31138794","title":"SORLA regulates endosomal trafficking and oncogenic fitness of HER2.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31138794","citation_count":60,"is_preprint":false},{"pmid":"29079999","id":"PMC_29079999","title":"Trafficking in Alzheimer's Disease: Modulation of APP Transport and Processing by the Transmembrane Proteins LRP1, SorLA, SorCS1c, Sortilin, and Calsyntenin.","date":"2017","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/29079999","citation_count":60,"is_preprint":false},{"pmid":"27822510","id":"PMC_27822510","title":"SORL1 mutations in early- and late-onset Alzheimer disease.","date":"2016","source":"Neurology. Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27822510","citation_count":59,"is_preprint":false},{"pmid":"10559012","id":"PMC_10559012","title":"Expression of LR11, a mosaic LDL receptor family member, is markedly increased in atherosclerotic lesions.","date":"1999","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10559012","citation_count":59,"is_preprint":false},{"pmid":"23333276","id":"PMC_23333276","title":"SorLA controls neurotrophic activity by sorting of GDNF and its receptors GFRα1 and RET.","date":"2013","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/23333276","citation_count":57,"is_preprint":false},{"pmid":"21385844","id":"PMC_21385844","title":"SorLA regulates the activity of lipoprotein lipase by intracellular trafficking.","date":"2011","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/21385844","citation_count":56,"is_preprint":false},{"pmid":"11956127","id":"PMC_11956127","title":"Enhanced expression of the LDL receptor family member LR11 increases migration of smooth muscle cells in vitro.","date":"2002","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/11956127","citation_count":55,"is_preprint":false},{"pmid":"26584636","id":"PMC_26584636","title":"Soluble LR11/SorLA represses thermogenesis in adipose tissue and correlates with BMI in humans.","date":"2015","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/26584636","citation_count":55,"is_preprint":false},{"pmid":"27466343","id":"PMC_27466343","title":"SNX27 and SORLA Interact to Reduce Amyloidogenic Subcellular Distribution and Processing of Amyloid Precursor Protein.","date":"2016","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/27466343","citation_count":55,"is_preprint":false},{"pmid":"21730226","id":"PMC_21730226","title":"Association of the Alzheimer's gene SORL1 with hippocampal volume in young, healthy adults.","date":"2011","source":"The American journal of psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/21730226","citation_count":54,"is_preprint":false},{"pmid":"22621900","id":"PMC_22621900","title":"GGA1-mediated endocytic traffic of LR11/SorLA alters APP intracellular distribution and amyloid-β production.","date":"2012","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/22621900","citation_count":53,"is_preprint":false},{"pmid":"30666202","id":"PMC_30666202","title":"Regulatory Roles of Sortilin and SorLA in Immune-Related Processes.","date":"2019","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30666202","citation_count":50,"is_preprint":false},{"pmid":"22836009","id":"PMC_22836009","title":"SORL1 and SIRT1 mRNA expression and promoter methylation levels in aging and Alzheimer's Disease.","date":"2012","source":"Neurochemistry international","url":"https://pubmed.ncbi.nlm.nih.gov/22836009","citation_count":50,"is_preprint":false},{"pmid":"19889229","id":"PMC_19889229","title":"Expression of SORL1 and a novel SORL1 splice variant in normal and Alzheimers disease brain.","date":"2009","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/19889229","citation_count":49,"is_preprint":false},{"pmid":"27322061","id":"PMC_27322061","title":"SORLA facilitates insulin receptor signaling in adipocytes and exacerbates obesity.","date":"2016","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/27322061","citation_count":48,"is_preprint":false},{"pmid":"27832290","id":"PMC_27832290","title":"Sorting receptor SORLA: cellular mechanisms and implications for disease.","date":"2016","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/27832290","citation_count":47,"is_preprint":false},{"pmid":"21147781","id":"PMC_21147781","title":"Rho kinase II phosphorylation of the lipoprotein receptor LR11/SORLA alters amyloid-beta production.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21147781","citation_count":47,"is_preprint":false},{"pmid":"15053742","id":"PMC_15053742","title":"The mosaic receptor sorLA/LR11 binds components of the plasminogen-activating system and platelet-derived growth factor-BB similarly to LRP1 (low-density lipoprotein receptor-related protein), but mediates slow internalization of bound ligand.","date":"2004","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/15053742","citation_count":47,"is_preprint":false},{"pmid":"20385770","id":"PMC_20385770","title":"SORLA/SORL1 functionally interacts with SPAK to control renal activation of Na(+)-K(+)-Cl(-) cotransporter 2.","date":"2010","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/20385770","citation_count":46,"is_preprint":false},{"pmid":"37611586","id":"PMC_37611586","title":"Cell-type-specific regulation of APOE and CLU levels in human neurons by the Alzheimer's disease risk gene SORL1.","date":"2023","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/37611586","citation_count":45,"is_preprint":false},{"pmid":"18713574","id":"PMC_18713574","title":"The neuronal sortilin-related receptor gene SORL1 and late-onset Alzheimer's disease.","date":"2008","source":"Current neurology and neuroscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/18713574","citation_count":44,"is_preprint":false},{"pmid":"19822782","id":"PMC_19822782","title":"Implication of sex and SORL1 variants in italian patients with Alzheimer disease.","date":"2009","source":"Archives of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/19822782","citation_count":43,"is_preprint":false},{"pmid":"28595629","id":"PMC_28595629","title":"Identification and description of three families with familial Alzheimer disease that segregate variants in the SORL1 gene.","date":"2017","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/28595629","citation_count":42,"is_preprint":false},{"pmid":"17826910","id":"PMC_17826910","title":"Association between genetic variants in sortilin-related receptor 1 (SORL1) and Alzheimer's disease in adults with Down syndrome.","date":"2007","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/17826910","citation_count":40,"is_preprint":false},{"pmid":"25482438","id":"PMC_25482438","title":"ApoE-isoform-dependent cellular uptake of amyloid-β is mediated by lipoprotein receptor LR11/SorLA.","date":"2014","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/25482438","citation_count":39,"is_preprint":false},{"pmid":"36099918","id":"PMC_36099918","title":"A genetically modified minipig model for Alzheimer's disease with SORL1 haploinsufficiency.","date":"2022","source":"Cell reports. Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36099918","citation_count":39,"is_preprint":false},{"pmid":"34619027","id":"PMC_34619027","title":"Brothers in arms: proBDNF/BDNF and sAPPα/Aβ-signaling and their common interplay with ADAM10, TrkB, p75NTR, sortilin, and sorLA in the progression of Alzheimer's disease.","date":"2021","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34619027","citation_count":38,"is_preprint":false},{"pmid":"26377460","id":"PMC_26377460","title":"Distinct Functions for Anterograde and Retrograde Sorting of SORLA in Amyloidogenic Processes in the Brain.","date":"2015","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/26377460","citation_count":38,"is_preprint":false},{"pmid":"29114064","id":"PMC_29114064","title":"SORLA attenuates EphA4 signaling and amyloid β-induced neurodegeneration.","date":"2017","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29114064","citation_count":37,"is_preprint":false},{"pmid":"25525276","id":"PMC_25525276","title":"SorLA complement-type repeat domains protect the amyloid precursor protein against processing.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25525276","citation_count":37,"is_preprint":false},{"pmid":"21997402","id":"PMC_21997402","title":"Impact of SORL1 single nucleotide polymorphisms on Alzheimer's disease cerebrospinal fluid markers.","date":"2011","source":"Dementia and geriatric cognitive disorders","url":"https://pubmed.ncbi.nlm.nih.gov/21997402","citation_count":36,"is_preprint":false},{"pmid":"26611835","id":"PMC_26611835","title":"Meta-analysis of the Association between Alzheimer Disease and Variants in GAB2, PICALM, and SORL1.","date":"2015","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/26611835","citation_count":35,"is_preprint":false},{"pmid":"19584446","id":"PMC_19584446","title":"A study of the SORL1 gene in Alzheimer's disease and cognitive function.","date":"2009","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/19584446","citation_count":34,"is_preprint":false},{"pmid":"35464477","id":"PMC_35464477","title":"Upregulated of ANXA3, SORL1, and Neutrophils May Be Key Factors in the Progressionof Ankylosing Spondylitis.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35464477","citation_count":33,"is_preprint":false},{"pmid":"28799085","id":"PMC_28799085","title":"Dimerization leads to changes in APP (amyloid precursor protein) trafficking mediated by LRP1 and SorLA.","date":"2017","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/28799085","citation_count":33,"is_preprint":false},{"pmid":"24166411","id":"PMC_24166411","title":"The SORL1 gene and convergent neural risk for Alzheimer's disease across the human lifespan.","date":"2013","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/24166411","citation_count":32,"is_preprint":false},{"pmid":"24001769","id":"PMC_24001769","title":"SORLA-dependent and -independent functions for PACS1 in control of amyloidogenic processes.","date":"2013","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/24001769","citation_count":30,"is_preprint":false},{"pmid":"23977241","id":"PMC_23977241","title":"SORLA-mediated trafficking of TrkB enhances the response of neurons to BDNF.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23977241","citation_count":30,"is_preprint":false},{"pmid":"16919601","id":"PMC_16919601","title":"Pitavastatin attenuates the PDGF-induced LR11/uPA receptor-mediated migration of smooth muscle cells.","date":"2006","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/16919601","citation_count":29,"is_preprint":false},{"pmid":"34922638","id":"PMC_34922638","title":"Impaired SorLA maturation and trafficking as a new mechanism for SORL1 missense variants in Alzheimer disease.","date":"2021","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/34922638","citation_count":29,"is_preprint":false},{"pmid":"25904844","id":"PMC_25904844","title":"Y682G Mutation of Amyloid Precursor Protein Promotes Endo-Lysosomal Dysfunction by Disrupting APP-SorLA Interaction.","date":"2015","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/25904844","citation_count":29,"is_preprint":false},{"pmid":"28527213","id":"PMC_28527213","title":"SORL1 Variants Show Different Association with Early-Onset and Late-Onset Alzheimer's Disease Risk.","date":"2017","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/28527213","citation_count":27,"is_preprint":false},{"pmid":"28034305","id":"PMC_28034305","title":"SORL1 gene, plasma biomarkers, and the risk of Alzheimer's disease for the Han Chinese population in Taiwan.","date":"2016","source":"Alzheimer's research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/28034305","citation_count":27,"is_preprint":false},{"pmid":"25659857","id":"PMC_25659857","title":"Influence of genetic variants in SORL1 gene on the manifestation of Alzheimer's disease.","date":"2014","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/25659857","citation_count":26,"is_preprint":false},{"pmid":"22286501","id":"PMC_22286501","title":"SORL1 genetic variants and cerebrospinal fluid biomarkers of Alzheimer’s disease.","date":"2012","source":"European archives of psychiatry and clinical neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/22286501","citation_count":25,"is_preprint":false},{"pmid":"22750733","id":"PMC_22750733","title":"Circulating soluble LR11/SorLA levels are highly increased and ameliorated by chemotherapy in acute leukemias.","date":"2012","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22750733","citation_count":24,"is_preprint":false},{"pmid":"9726247","id":"PMC_9726247","title":"Developmental regulation of LR11 expression in murine brain.","date":"1998","source":"DNA and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/9726247","citation_count":23,"is_preprint":false},{"pmid":"24699135","id":"PMC_24699135","title":"Tetraspanin CD9 modulates ADAM17-mediated shedding of LR11 in leukocytes.","date":"2014","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24699135","citation_count":23,"is_preprint":false},{"pmid":"23948893","id":"PMC_23948893","title":"An updated meta-analysis of the association between SORL1 variants and the risk for sporadic Alzheimer's disease.","date":"2013","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/23948893","citation_count":23,"is_preprint":false},{"pmid":"22045485","id":"PMC_22045485","title":"Interrelations between CSF soluble AβPPβ, amyloid-β 1-42, SORL1, and tau levels in Alzheimer's disease.","date":"2012","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/22045485","citation_count":23,"is_preprint":false},{"pmid":"26858303","id":"PMC_26858303","title":"Cytokine-Like Factor 1, an Essential Facilitator of Cardiotrophin-Like Cytokine:Ciliary Neurotrophic Factor Receptor α Signaling and sorLA-Mediated Turnover.","date":"2016","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/26858303","citation_count":23,"is_preprint":false},{"pmid":"23486467","id":"PMC_23486467","title":"The soluble form of LR11 protein is a regulator of hypoxia-induced, urokinase-type plasminogen activator receptor (uPAR)-mediated adhesion of immature hematological cells.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23486467","citation_count":22,"is_preprint":false},{"pmid":"38244079","id":"PMC_38244079","title":"A familial missense variant in the Alzheimer's disease gene SORL1 impairs its maturation and endosomal sorting.","date":"2024","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/38244079","citation_count":22,"is_preprint":false},{"pmid":"22297619","id":"PMC_22297619","title":"Sortilin and SorLA regulate neuronal sorting of trophic and dementia-linked proteins.","date":"2012","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/22297619","citation_count":21,"is_preprint":false},{"pmid":"33420373","id":"PMC_33420373","title":"A feed-forward loop between SorLA and HER3 determines heregulin response and neratinib resistance.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/33420373","citation_count":21,"is_preprint":false},{"pmid":"19653016","id":"PMC_19653016","title":"Sequence variation in SORL1 and dementia risk in Swedes.","date":"2009","source":"Neurogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/19653016","citation_count":21,"is_preprint":false},{"pmid":"32601248","id":"PMC_32601248","title":"Soluble SORLA Enhances Neurite Outgrowth and Regeneration through Activation of the EGF Receptor/ERK Signaling Axis.","date":"2020","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/32601248","citation_count":21,"is_preprint":false},{"pmid":"17121844","id":"PMC_17121844","title":"N-linked oligosaccharides on the low density lipoprotein receptor homolog SorLA/LR11 are modified with terminal GalNAc-4-SO4 in kidney and brain.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17121844","citation_count":21,"is_preprint":false},{"pmid":"28265003","id":"PMC_28265003","title":"SorLA in Interleukin-6 Signaling and Turnover.","date":"2017","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/28265003","citation_count":20,"is_preprint":false},{"pmid":"36652482","id":"PMC_36652482","title":"Dimerization of the Alzheimer's disease pathogenic receptor SORLA regulates its association with retromer.","date":"2023","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/36652482","citation_count":19,"is_preprint":false},{"pmid":"25450149","id":"PMC_25450149","title":"SORL1 gene polymorphism association with late-onset Alzheimer's disease.","date":"2014","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/25450149","citation_count":19,"is_preprint":false},{"pmid":"37949073","id":"PMC_37949073","title":"Pharmacologic enhancement of retromer rescues endosomal pathology induced by defects in the Alzheimer's gene SORL1.","date":"2023","source":"Stem cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/37949073","citation_count":19,"is_preprint":false},{"pmid":"39226352","id":"PMC_39226352","title":"The SORL1 p.Y1816C variant causes impaired endosomal dimerization and autosomal dominant Alzheimer's disease.","date":"2024","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/39226352","citation_count":18,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51221,"output_tokens":12670,"usd":0.171856,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":24300,"output_tokens":6917,"usd":0.147212,"stage2_stop_reason":"end_turn"},"total_usd":0.319068,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2005,\n      \"finding\": \"SorLA/LR11 directly interacts with APP in vitro and in living cells, colocalizes with APP in endosomal and Golgi compartments, and acts as a sorting receptor that redistributes APP to the Golgi, reducing processing to Aβ. Ablation of SorLA in knockout mice increases brain Aβ levels.\",\n      \"method\": \"Co-immunoprecipitation, colocalization imaging, overexpression in neurons, SorLA-knockout mouse model\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, colocalization, in vivo KO phenotype, replicated across multiple labs\",\n      \"pmids\": [\"16174740\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"SorLA's cytoplasmic domain contains an acidic cluster-dileucine-like motif and a GGA-binding site that mediate Golgi-endosome transport and AP-2-dependent endocytosis. AP-1 adaptor complex is essential for SorLA transport between Golgi membranes and endosomes; SNX1 and Vps35 (retromer components) are engaged in retraction of the receptor from endosomes.\",\n      \"method\": \"Chimeric receptor constructs, AP-1 mu1-chain-deficient cells, co-immunoprecipitation, trafficking assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — mutagenesis of sorting motifs, functional rescue experiments, multiple orthogonal approaches in one study\",\n      \"pmids\": [\"17646382\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"SorLA acts as a retention factor for APP in trans-Golgi compartments/TGN, preventing release into processing pathways. Proper localization depends on functional interaction with adaptors GGA and PACS-1; aberrant targeting to the recycling compartment or plasma membrane causes faulty APP trafficking and increased amyloidogenic processing.\",\n      \"method\": \"Overexpression, dominant-negative adaptor proteins, subcellular fractionation, Aβ ELISA\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple adaptor perturbation experiments, functional APP processing readout, single lab with orthogonal approaches\",\n      \"pmids\": [\"17855360\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"SorLA interacts with both APP (via cytoplasmic C99 domain) and BACE1 by co-immunoprecipitation, and reduces BACE-APP interactions in the Golgi as measured by FRET. Both full-length SorLA and a sorLA tail construct inhibited BACE-dependent APP cleavage, reducing secreted Aβ.\",\n      \"method\": \"Co-immunoprecipitation, FRET assay, APP-shedding assay, BACE overexpression\",\n      \"journal\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — FRET, Co-IP, and functional cleavage assay; multiple orthogonal methods in single study\",\n      \"pmids\": [\"16407538\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"The binding site between SorLA and APP was mapped to the cluster of complement-type repeats (CR-cluster) in SorLA and the carbohydrate-linked domain of APP, forming a 1:1 stoichiometric complex, as determined by surface plasmon resonance and analytical ultracentrifugation of recombinant fragments.\",\n      \"method\": \"FRET assay, surface plasmon resonance, analytical ultracentrifugation of recombinant fragments\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstitution with recombinant fragments, multiple biophysical methods (SPR + ultracentrifugation + FRET), single lab\",\n      \"pmids\": [\"16489755\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"SORL1 directs trafficking of APP into recycling endosomal pathways; when SORL1 is underexpressed, APP is sorted into Aβ-generating compartments. Inherited SORL1 variants occur in intronic clusters that may regulate tissue-specific SORL1 expression.\",\n      \"method\": \"siRNA knockdown of SORL1, APP trafficking assay, genetic association study\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function with defined cellular phenotype (APP mis-sorting), replicated in multiple populations\",\n      \"pmids\": [\"17220890\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"SorLA is synthesized as a proreceptor cleaved by furin in late Golgi compartments, activating the Vps10p domain for ligand binding. Following activation, SorLA binds neuropeptides, receptor-associated protein, ApoE, and lipoprotein lipase, and mediates endocytosis; ~10% of full-length SorLA is expressed at the cell surface while the major pool resides in late Golgi.\",\n      \"method\": \"Furin cleavage assay, ligand binding assays, cell surface expression quantification, endocytosis assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro furin cleavage, multiple ligand binding assays, functional endocytosis readout\",\n      \"pmids\": [\"11294867\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"The SorLA cytoplasmic tail binds adaptor proteins GGA1 and GGA2 via three critical C-terminal residues conforming to a novel motif (ψ-ψ-X-X-φ), distinct from the acidic cluster-dileucine motifs used by sortilin and mannose-6-phosphate receptors.\",\n      \"method\": \"Co-immunoprecipitation, mutagenesis of cytoplasmic tail residues\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with mutagenesis to define critical residues, single lab\",\n      \"pmids\": [\"11821067\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"SorLA contains a FANSHY sequence in its cytoplasmic domain recognized by the VPS26 subunit of the retromer complex. Mutations in the VPS26 binding site redistribute SorLA to endosomes (away from TGN) without affecting APP binding, but cause APP mis-sorting into a non-Golgi compartment with increased amyloidogenic processing.\",\n      \"method\": \"Mutagenesis of FANSHY motif, VPS26 knockdown, subcellular fractionation, Aβ ELISA, co-immunoprecipitation\",\n      \"journal\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — site-directed mutagenesis of sorting motif, functional rescue, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"22279231\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The VPS10P domain of SORLA binds nascent Aβ peptides and directs them to lysosomes for degradation. A familial AD mutation in SORL1 impairs this Aβ binding. SORLA overexpression in mice decreases brain Aβ levels via lysosomal targeting.\",\n      \"method\": \"Binding assay with recombinant VPS10P domain, SORLA-overexpressing mouse model, lysosomal targeting assay, site-directed mutagenesis\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro binding, transgenic mouse model, mutagenesis of binding domain, multiple orthogonal methods\",\n      \"pmids\": [\"24523320\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ROCK2 (Rho-associated coiled-coil containing protein kinase 2) binds LR11/SorLA and phosphorylates it at serine 2206 in the cytoplasmic tail. ROCK2 inhibition reduces LR11 phosphorylation and ectodomain shedding while increasing intracellular LR11 levels. Phosphorylation at S2206 is required for LR11-mediated reduction of Aβ.\",\n      \"method\": \"32P-labeling, LC-MS/MS identification of ROCK2 as binding partner, co-immunoprecipitation from human brain, ROCK inhibitor treatment, siRNA knockdown of ROCK2, S2206A mutagenesis, in vitro kinase assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — mass spectrometry identification, in vitro phosphorylation assay, site-directed mutagenesis, Co-IP from human brain; multiple orthogonal methods\",\n      \"pmids\": [\"21147781\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"SorLA acts as a sorting receptor for the GDNF/GFRα1 complex, directing it from the cell surface to endosomes and then to lysosomes for GDNF degradation while GFRα1 recycles, creating a GDNF clearance pathway. SorLA also targets RET for endocytosis but not degradation. SorLA-deficient mice display elevated GDNF levels, altered dopaminergic function, hyperactivity, and reduced anxiety.\",\n      \"method\": \"SorLA-deficient mouse model, co-immunoprecipitation, endocytosis/degradation assays, behavioral phenotyping\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — KO mouse phenotype, Co-IP, and functional sorting assays; multiple readouts and replicated phenotypes\",\n      \"pmids\": [\"23333276\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"SorLA regulates intracellular trafficking of lipoprotein lipase (LPL) by binding LPL under neutral and acidic conditions. SorLA expression redistributes LPL to endosomes and routes it to lysosomes for degradation, resulting in ~80% reduction of LPL activity in expressing cells.\",\n      \"method\": \"Co-immunoprecipitation, subcellular fractionation, LPL activity assay, immunofluorescence colocalization in primary neurons\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — binding confirmed by Co-IP, functional enzyme activity assay, single lab with two orthogonal methods\",\n      \"pmids\": [\"21385844\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"SORLA is expressed in epithelial cells of the thick ascending limb (TAL) of Henle's loop and functionally interacts with SPAK (Ste-20-related proline-alanine-rich kinase). SORLA deficiency causes missorting of SPAK, inability to phosphorylate NKCC2 cotransporter, and inability to reabsorb sodium and chloride during osmotic stress.\",\n      \"method\": \"SORLA-deficient mouse model, immunolocalization, co-immunoprecipitation of SORLA and SPAK, NKCC2 phosphorylation assays, renal ion transport measurements\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO mouse with defined physiological phenotype, Co-IP, phosphorylation assay; multiple orthogonal methods\",\n      \"pmids\": [\"20385770\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"SORLA is a sorting factor for the BDNF receptor TrkB, facilitating trafficking of TrkB between synaptic plasma membranes, post-synaptic densities, and cell soma. Loss of SORLA impairs neuritic transport of TrkB and blunts BDNF response in primary neurons; SORLA deficiency aggravates neuromotoric deficits in a Huntington's disease mouse model.\",\n      \"method\": \"SORLA KO neurons, live-cell imaging of TrkB trafficking, BDNF signaling assays, Huntington's disease mouse model cross\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with defined trafficking and signaling phenotype, in vivo model; single lab\",\n      \"pmids\": [\"23977241\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"SORLA acts as a sorting factor for the insulin receptor (IR) in adipocytes, redirecting internalized IR from endosomes to the plasma membrane, thereby enhancing IR surface expression and strengthening insulin signal reception. Gene-dosage effects link SORLA expression to obesity and glucose tolerance in mouse models and human subjects.\",\n      \"method\": \"Mouse models with genetic loss or adipose-specific overexpression of SORLA, insulin receptor trafficking assay, co-immunoprecipitation, lipolysis assays\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple mouse models (KO and tissue-specific OE), receptor trafficking assay, Co-IP, functional metabolic readouts\",\n      \"pmids\": [\"27322061\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Soluble LR11/SorLA (sLR11) suppresses thermogenesis in adipose tissue in a cell-autonomous manner via the BMP/TGFβ signaling pathway, reducing Smad phosphorylation. LR11-deficient mice are protected from diet-induced obesity with increased browning of white adipose tissue.\",\n      \"method\": \"LR11-KO mouse model, treatment of adipocytes with sLR11, Smad phosphorylation assay, metabolic phenotyping\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO mouse phenotype with mechanistic pathway (Smad phosphorylation assay), cell-autonomous rescue with purified sLR11; multiple orthogonal methods\",\n      \"pmids\": [\"26584636\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"After TACE-mediated ectodomain shedding of SorLA, the remaining C-terminal membrane fragment is processed by γ-secretase, releasing the SorLA cytoplasmic domain and a SorLA β-peptide. The released cytoplasmic domain translocates to the nucleus (dependent on an intact NLS) and acts as a transcriptional activator in reporter gene assays.\",\n      \"method\": \"γ-secretase inhibitors, dominant-negative presenilin mutants, presenilin knockout cells, in vitro γ-secretase assay, EGFP fusion reporter, nuclear translocation imaging, reporter gene assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro cleavage assay, genetic presenilin KO validation, NLS mutagenesis, reporter gene assay; multiple orthogonal methods\",\n      \"pmids\": [\"16531402\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"SorLA binds the neuropeptide head activator (HA) at the cell surface; HA stimulates metalloprotease-mediated ectodomain shedding of SorLA, translocation of SorLA from internal membranes to the cell surface, and enhanced SorLA synthesis. Blockade of SorLA shedding or antisense oligonucleotides against SorLA decreases HA-induced cell proliferation.\",\n      \"method\": \"HA-Sepharose pulldown, metalloprotease inhibitor treatment, SorLA antisense oligonucleotides, cell proliferation assay, immunostaining of SorLA subcellular localization\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — affinity pulldown, pharmacological inhibition, antisense knockdown with functional readout; single lab\",\n      \"pmids\": [\"11082041\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"LR11 overexpressed in hamster cells binds ApoE-rich lipoproteins (β-VLDL) with high affinity (similar to LDLR and VLDLR), internalizes and degrades bound β-VLDL, and promotes accumulation of cholesteryl esters and lipid droplets. RAP and β-VLDL compete for binding.\",\n      \"method\": \"Binding and internalization assays in LR11-transfected cells, cholesteryl ester assay, lipid droplet staining, competition assays with RAP\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional binding, internalization, and degradation assays with transfected cells; single lab, multiple assays\",\n      \"pmids\": [\"11557679\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"LR11 forms complexes with urokinase-type plasminogen activator receptor (uPAR) on the cell surface and inhibits LRP-mediated internalization of uPAR, resulting in increased uPAR surface localization. Both cell-anchored and secreted soluble LR11 bind uPAR. In smooth muscle cells, LR11 mediates enhanced migration through upregulation of surface uPAR levels. Neutralization of LR11 reduces cuff-induced intimal thickness in mice.\",\n      \"method\": \"Co-immunoprecipitation, uPAR internalization assay, migration assay, anti-LR11 antibody neutralization in vivo\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, functional migration assay, in vivo neutralization; single lab with multiple methods\",\n      \"pmids\": [\"14764453\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"SorLA/LR11 binds components of the plasminogen-activating system (uPA, PAI-1, uPAR) and PDGF-BB similarly to LRP1, but mediates much slower internalization of bound ligand than LRP1. SorLA is substantially less efficient as a clearance receptor than LRP1, and can divert ligands from LRP1-mediated clearance.\",\n      \"method\": \"Binding assays in LRP1-deficient cells transfected with sorLA, ligand internalization rate measurements, competition assays\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — quantitative internalization assays in isogenic LRP1-deficient cells, binding comparison; single lab\",\n      \"pmids\": [\"15053742\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"GGA1 specifically regulates LR11 endocytic trafficking; mutagenesis of the GGA-binding (DXXLL-like) motif in LR11 alters its endosomal distribution and its effects on APP trafficking and Aβ production. siRNA knockdown of GGA1 (but not GGA2 or GGA3) is necessary for both LR11 and BACE1 modulation of APP processing. BACE1-S498A mutation enhances BACE1 targeting to LR11-positive compartments and nullifies LR11-mediated Aβ reduction.\",\n      \"method\": \"siRNA knockdown of individual GGAs, GGA-binding site mutagenesis, Aβ ELISA, APP trafficking assay, BACE1 mutagenesis\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — selective siRNA knockdown with functional readout, mutagenesis; single lab with multiple approaches\",\n      \"pmids\": [\"22621900\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Disruption of SORLA-PACS1 interaction (via transgenic mice expressing PACS1-binding-defective SORLA mutant) prevents SORLA/APP complexes from sorting to the TGN in neurons, increasing APP processing in the brain. Loss of PACS1 also impairs expression of cation-independent mannose-6-phosphate receptor and cathepsin B, providing a SORLA-independent mechanism for Aβ catabolism control.\",\n      \"method\": \"Transgenic mice expressing PACS1-binding mutant of SORLA, neuronal cell line knockdown, cathepsin B assay, APP processing assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo transgenic mouse model with specific trafficking mutation, multiple downstream readouts; single lab\",\n      \"pmids\": [\"24001769\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The SorLA CR-cluster (complement-type repeat domains) is essential for interaction with APP; deletion abolishes protection against APP processing. Mutation of fingerprint residues in CR-domains alters O-linked glycosylation of APP in the Golgi. These results identify CR-domain-mediated control of APP glycosylation as a mechanism by which SorLA protects APP from amyloidogenic processing.\",\n      \"method\": \"Stable SorLA CR-deletion and CR-mutant cell lines, co-immunoprecipitation, Aβ/sAPP ELISA, glycosylation analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — domain deletion and mutagenesis with functional readout, glycosylation assay; single lab\",\n      \"pmids\": [\"25525276\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Distinct anterograde (GGA-mediated) and retrograde (retromer-mediated) SORLA trafficking routes serve discrete functions: retromer-binding disruption causes SORLA accumulation in endosomes and enhanced APP processing, while GGA-binding disruption does not affect APP processing but causes increased brain Aβ levels attributed to a defect in anterograde lysosomal targeting of Aβ.\",\n      \"method\": \"Transgenic mice expressing GGA-binding or retromer-binding mutant SORLA, brain Aβ measurement, APP processing assays, subcellular fractionation\",\n      \"journal\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo mouse models with specific trafficking mutations, dual pathway dissection; multiple orthogonal readouts\",\n      \"pmids\": [\"26377460\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"SNX27 binds to the SORLA cytosolic tail to form a ternary complex with APP. SNX27 enhances cell surface SORLA and APP levels, and depletion of SNX27 or SORLA reduces APP endosome-to-cell surface recycling kinetics. SNX27 overexpression enhances non-amyloidogenic APP cleavage products in a SORLA-dependent manner.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown of SNX27/SORLA, APP recycling kinetics assay, surface APP cleavage product measurement\",\n      \"journal\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with functional trafficking assay, epistasis via double knockdown; single lab\",\n      \"pmids\": [\"27466343\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"SORLA interacts with the EphA4 receptor tyrosine kinase and attenuates ephrinA1-induced EphA4 clustering and activation, limiting downstream EphA4 signaling in neurons. SORLA transgenic mice show decreased EphA4 activation and redistribution to postsynaptic densities with milder Aβ oligomer-induced deficits in LTP and memory. Active EphA4 levels in human AD brains are inversely correlated with SORLA/EphA4 association.\",\n      \"method\": \"Co-immunoprecipitation, EphA4 activation assay, SORLA transgenic mouse model, LTP and memory behavioral tests, human AD brain analysis\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, in vivo transgenic model, functional signaling assay; single lab with multiple methods\",\n      \"pmids\": [\"29114064\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SORLA co-precipitates with HER2 in cancer cells and promotes recycling of endosomal HER2 back to the plasma membrane via Rab4-dependent pathway. Depletion of SORLA triggers HER2 targeting to late endosomal/lysosomal compartments, impairs HER2-driven signaling, reduces in vivo tumor growth, and sensitizes cells to lysosome-targeting drugs.\",\n      \"method\": \"Co-immunoprecipitation, subcellular fractionation, SORLA siRNA depletion, Rab4-dependent trafficking assay, in vivo tumor growth assay\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, functional in vivo tumor model, defined trafficking mechanism (Rab4-dependent), multiple orthogonal methods\",\n      \"pmids\": [\"31138794\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"SORL1 depletion in hiPSC-derived neurons (but not microglia) causes early endosome enlargement and altered localization of APP in early endosomes. BACE inhibition does not rescue endosome enlargement, demonstrating that this phenotype is independent of amyloidogenic APP processing.\",\n      \"method\": \"CRISPR-Cas9 SORL1 depletion in hiPSCs, endosome size quantification by confocal microscopy, BACE inhibitor treatment, cell-type-specific comparison (neurons vs. microglia)\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — isogenic CRISPR KO, cell-type specificity demonstrated, pharmacological epistasis (BACE inhibitor) to separate mechanism; multiple orthogonal approaches\",\n      \"pmids\": [\"32492427\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SORL1 truncating mutation causes haploinsufficiency and enlarged endosomes in human neurons. Complete loss of SORL1 causes additional defects in lysosome function and autophagy. Neuronal endolysosomal dysfunction from SORL1 loss is relieved by antisense oligonucleotide-mediated reduction of APP, placing PSEN1, APP, and SORL1 in a common pathway regulating the endolysosomal system.\",\n      \"method\": \"CRISPR-Cas9 truncating mutation in hiPSCs, isogenic WT/heterozygous/homozygous null neurons, endosome/lysosome functional assays, autophagy assay, APP-targeting antisense oligonucleotides\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — isogenic CRISPR series (WT/het/null), gene-dosage effects, epistasis via ASO rescue; multiple orthogonal methods\",\n      \"pmids\": [\"34133918\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Loss of SORL1 impairs endosomal trafficking of GLUA1, TRKB, and APP in hiPSC-derived neurons, increasing lysosomal targeting and reducing recycling endosome-to-cell surface delivery. SORL1 depletion reduces synaptic activity (measured by MEA). Increased SORL1 expression enhances endosomal recycling of APP and GLUA1.\",\n      \"method\": \"Isogenic hiPSC-derived neurons with SORL1 depletion or overexpression, confocal microscopy of endosomal trafficking, cell surface recycling and lysosomal degradation assays, MEA, RNA sequencing\",\n      \"journal\": \"Cellular and molecular life sciences : CMLS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — isogenic CRISPR models, multiple cargo proteins tested, functional MEA readout, transcriptomic validation; multiple orthogonal methods\",\n      \"pmids\": [\"35226190\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Rare SORL1 missense variants (R332W, S577P, R654W) cause impaired maturation and trafficking of the SorLA protein, with retention in the endoplasmic reticulum and reduced delivery to the plasma membrane and endosomal system. Expression of R332W and R654W in hiPSCs is associated with increased Aβ secretion, demonstrating a loss-of-function effect.\",\n      \"method\": \"Overexpression of 70 SorLA variants in HEK293 cells, CRISPR/Cas9-modified hiPSCs expressing endogenous variants, ER retention assay, plasma membrane delivery assay, Aβ ELISA, structural analysis\",\n      \"journal\": \"Acta neuropathologica communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — large-scale variant screen plus endogenous-level CRISPR validation, ER retention mechanism, functional Aβ readout; multiple methods\",\n      \"pmids\": [\"34922638\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Activation of the α2A adrenergic receptor (α2AAR) signaling disrupts APP interaction with SorLA in cells and in mouse brain, reduces Golgi localization of APP, promotes APP distribution in endosomes, and increases β-secretase cleavage and Aβ generation.\",\n      \"method\": \"α2AAR genetic deficiency and pharmacological activation, APP-SorLA co-immunoprecipitation in cells and mouse brain, subcellular APP localization by immunofluorescence, Aβ ELISA\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP from brain tissue, KO and pharmacological perturbation, subcellular localization; single lab\",\n      \"pmids\": [\"25404298\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"SORLA disruption of retromer binding results in SORLA accumulation in endosomes and depletion from TGN, with overall enhanced APP processing. Disruption of GGA interaction does not affect APP processing but increases brain Aβ, attributed to defect in anterograde lysosomal Aβ targeting.\",\n      \"method\": \"Mouse models expressing SORLA variants lacking retromer or GGA binding sites, brain Aβ measurement, TGN localization assay\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo mouse models with trafficking mutants; review/perspective but citing primary mouse model data\",\n      \"pmids\": [\"23813966\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"LR11/SorLA mediates cellular uptake of Aβ in an ApoE-isoform-dependent manner. Co-immunoprecipitation reveals apoE4 forms a stronger complex with LR11 than apoE3 or apoE2 (apoE4>apoE3>apoE2). ApoE4 most prominently accentuates LR11-mediated cellular uptake of extracellular Aβ in a coculture assay.\",\n      \"method\": \"Co-immunoprecipitation, cellular uptake assay with FAM-labeled Aβ in coculture, LR11 overexpression\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — Co-IP and uptake assay; single lab, functional readout but limited mechanistic depth\",\n      \"pmids\": [\"25482438\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"SorLA acts as an APP-sorting receptor distinct from sortilin: SorLA mainly colocalizes with APP in the soma and inhibits generation of all soluble APP products, whereas sortilin interacts with APP in neurites and promotes α-secretase cleavage. Both SorLA and sortilin bind soluble APP (sAPP) via the 6A domain and mediate its internalization to different compartments.\",\n      \"method\": \"Co-immunoprecipitation, subcellular colocalization imaging, sAPP binding/internalization assay, α-secretase cleavage assay\",\n      \"journal\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, functional processing assays, domain mapping; single lab\",\n      \"pmids\": [\"23283322\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"APP mutations in the YENPTY domain (Y682G) disrupt APP complex formation with SorLA, causing endo-lysosomal dysfunction and neuronal degeneration, and alter SorLA trafficking resulting in increased SorLA secretion.\",\n      \"method\": \"APP Y682G knock-in mouse model, co-immunoprecipitation of APP/SorLA, subcellular localization of SorLA, lysosomal function assay\",\n      \"journal\": \"Frontiers in cellular neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knock-in mouse model, Co-IP, functional endolysosomal readout; single lab\",\n      \"pmids\": [\"25904844\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Soluble SORLA (sSORLA) coprecipitates with EGF receptor (EGFR) in vitro, increases EGFR Y1173 phosphorylation, and activates ERK signaling and Fos transcription in neurons. sSORLA promotes neurite outgrowth and regeneration; pharmacological EGFR or ERK inhibition reverses these effects.\",\n      \"method\": \"Co-precipitation of sSORLA and EGFR, EGFR phosphorylation assay, ERK activation assay, pharmacological inhibitors, neurite outgrowth assay, RNAseq in SORLA transgenic mouse hippocampus\",\n      \"journal\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-precipitation, phosphorylation assay, pharmacological epistasis, in vivo transcriptomics; single lab\",\n      \"pmids\": [\"32601248\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"SorLA mediates cellular uptake of IL-6 and circulating IL-6R in astrocytes, interacts with membrane-bound IL-6R at the cell surface to downregulate IL-6 cis-signaling, and the shed SorLA ectodomain stabilizes IL-6 and facilitates its trans-signaling.\",\n      \"method\": \"Co-immunoprecipitation of SorLA and IL-6R, IL-6 and IL-6R uptake assay, IL-6 signaling assay, ectodomain shedding assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, functional signaling and uptake assays; single lab\",\n      \"pmids\": [\"28265003\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CLF-1 has independent binding sites for CLC, CNTFRα, and SorLA. SorLA promotes downregulation of CNTFRα pool in stimulated cells via its endocytic receptor activity, and may bind and concentrate the tripartite soluble CLC:CLF-1:CNTFRα complex on cell membranes to facilitate gp130/LIFRβ signaling.\",\n      \"method\": \"Binding assays, co-immunoprecipitation, CNTFRα turnover assay, signaling assays with CLF-1 mutants\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple binding assays, functional signaling readout, site-specific mutagenesis of binding regions; single lab\",\n      \"pmids\": [\"26858303\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Tetraspanin CD9 modulates ADAM17-mediated shedding of LR11 on leukocyte surfaces. CD9 overexpression reduces sLR11 release; anti-CD9 antibody treatment or CD9 shRNA knockdown increases sLR11 shedding, which is blocked by a metalloprotease inhibitor.\",\n      \"method\": \"CD9 overexpression and shRNA knockdown, anti-CD9 neutralizing antibodies, metalloprotease inhibitor treatment, sLR11 ELISA, confocal colocalization\",\n      \"journal\": \"Experimental & molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function for CD9 with pharmacological validation of ADAM17 dependence; single lab\",\n      \"pmids\": [\"24699135\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"N-linked oligosaccharides in the VPS10p domain of SorLA/LR11 are modified with terminal β1,4-linked GalNAc-4-SO4 in kidney and brain. Two sequences with basic amino acids within the Vps10p domain mediate recognition by GalNAcTIII and GalNAcTIV transferases.\",\n      \"method\": \"Biochemical isolation of oligosaccharides, co-expression of Vps10p domain with GalNAcTIII/IV, domain mutagenesis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — biochemical glycan characterization, enzyme co-expression assay, domain mapping; single lab\",\n      \"pmids\": [\"17121844\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SORL1 loss in iPSC-derived neurons causes neuron-specific reduction in APOE and CLU protein levels and altered lipid profiles. Enhancement of retromer-mediated trafficking rescues tau phenotypes but not APOE levels. TGF-β/SMAD signaling is implicated in SORL1 function regulating APOE RNA levels in a SORL1-dependent manner.\",\n      \"method\": \"SORL1-null iPSC-derived neurons, astrocytes, microglia, endothelial cells; retromer enhancer treatment; SMAD pathway modulation; APOE/CLU protein quantification; RNA-seq\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — isogenic CRISPR KO in multiple cell types, pharmacological pathway dissection, transcriptomic validation; single lab\",\n      \"pmids\": [\"37611586\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SORLA dimerizes via its fibronectin-type-III (3Fn) and VPS10p domains within retromer-positive endosomal tubules. A SORLA fragment comprising 3Fn, transmembrane, and cytoplasmic domains forms dimers and enhances retromer-dependent APP recycling and decreases amyloidogenic processing.\",\n      \"method\": \"X-ray crystallography, AI-based structural modeling, SORLA domain fragment expression and dimerization assays, APP recycling assay, Aβ measurement\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystallographic evidence plus functional domain fragment validation; multiple orthogonal approaches\",\n      \"pmids\": [\"36652482\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"The SORL1 p.Y1816C variant impairs SORLA homodimerization in the endosome, leading to decreased trafficking to the cell surface and reduced sSORLA shedding. iPSC-derived neurons with engineered p.Y1816C have enlarged endosomes. The trafficking defect can be rescued by expression of the SORLA 3Fn-minireceptor.\",\n      \"method\": \"Segregation analysis in three families, CRISPR-engineered iPSC-derived neurons, dimerization assay, cell surface trafficking assay, sSORLA shedding measurement, endosome size quantification, 3Fn-minireceptor rescue\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — isogenic CRISPR neurons, dimerization assay, functional rescue; multiple orthogonal methods\",\n      \"pmids\": [\"39226352\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SorLA forms a trimeric complex with HER2 and HER3, attenuating lysosomal degradation of the HER2-HER3 dimer in a Rab4-dependent manner. Heregulin-mediated signaling supports SorLA transcription downstream of the MAPK pathway. SorLA loss compromises heregulin-induced proliferation and sensitizes anti-HER2 therapy-resistant breast cancer cells to neratinib.\",\n      \"method\": \"Co-immunoprecipitation of SorLA/HER2/HER3, SorLA siRNA depletion, Rab4 trafficking assay, heregulin signaling assay, cancer spheroid and zebrafish xenograft models\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — trimeric complex Co-IP, in vivo zebrafish model, Rab4-dependent mechanism; single lab\",\n      \"pmids\": [\"33420373\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SORL1 haploinsufficiency in Göttingen minipigs (via CRISPR-Cas9) phenocopies the preclinical in vivo AD profile seen with APP, PSEN1, and PSEN2 mutations, resulting in elevated Aβ and tau levels preceding amyloid plaque formation.\",\n      \"method\": \"CRISPR-Cas9 gene editing in minipigs, CSF and plasma biomarker measurements (Aβ, tau)\",\n      \"journal\": \"Cell reports. Medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — large animal gene-edited model with AD-relevant biomarkers; single study\",\n      \"pmids\": [\"36099918\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"The familial AD SORL1 p.R953C variant, occurring in the YWTD-domain, causes retention of SORL1 in the endoplasmic reticulum, decreased receptor maturation and shedding, and impaired endosomal trafficking.\",\n      \"method\": \"Family segregation analysis, SORL1 variant functional characterization in cell lines, ER retention assay, maturation/shedding assay, endosomal trafficking assay\",\n      \"journal\": \"Acta neuropathologica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — variant characterization with ER retention and shedding assays; single lab, multiple complementary assays\",\n      \"pmids\": [\"38244079\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"The soluble form of LR11 (sLR11) regulates hypoxia-induced, uPAR-mediated adhesion of hematopoietic stem and progenitor cells (HSPCs) to stromal cells. Hypoxia induces HIF-1α binding to the LR11 promoter, increasing LR11 expression and sLR11 production. sLR11 co-immunoprecipitates with uPAR and enhances HSPC attachment; attachment is reduced by anti-uPAR antibodies.\",\n      \"method\": \"LR11-KO mouse HSPC adhesion assay, sLR11 treatment, anti-uPAR blocking, HIF-1α knockdown, HIF-1α ChIP at LR11 promoter, co-immunoprecipitation of LR11/uPAR\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, KO mouse, HIF-1α ChIP, functional adhesion assay; single lab with multiple methods\",\n      \"pmids\": [\"23486467\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SORL1/SORLA is a large multidomain type-I transmembrane sorting receptor that shuttles between the trans-Golgi network, endosomes, and the cell surface through interactions with cytosolic adaptors (GGA1/2, PACS-1, retromer via VPS26-FANSHY, AP-1, AP-2, SNX27); it binds APP via its complement-type repeat cluster and the VPS10P domain sequesters nascent Aβ for lysosomal degradation, thereby limiting amyloidogenic processing—with retromer-mediated retrograde trafficking suppressing APP processing and GGA-mediated anterograde trafficking directing Aβ to lysosomes; additionally, SORLA regulates endosomal recycling of multiple cargoes (GLUA1, TRKB, HER2, insulin receptor) and controls signaling by GDNF/GFRα1, IL-6, CLF-1:CLC:CNTFRα, and EphA4, while its shed ectodomain activates EGFR/ERK neurite outgrowth signaling, and its phosphorylation by ROCK2 at S2206 modulates ectodomain shedding; loss-of-function—whether by gene knockout, CRISPR haploinsufficiency, or missense variants causing ER retention or dimerization defects—consistently causes early endosome enlargement, increased APP processing to Aβ, and endolysosomal dysfunction in neurons.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"SORL1/SORLA is a large multidomain type-I transmembrane sorting receptor that governs the intracellular trafficking of amyloid precursor protein (APP) and a broad set of other cargoes through the trans-Golgi network (TGN), endosomal, and cell-surface compartments, and its loss is a central driver of the endolysosomal pathology underlying Alzheimer's disease [#0, #5, #30]. Synthesized as a furin-cleaved proreceptor whose VPS10P domain becomes competent for ligand binding [#6], SORLA binds APP directly through its complement-type repeat (CR) cluster to form a 1:1 complex, retains APP in the TGN, reduces its co-residence with BACE1, and thereby suppresses amyloidogenic processing to A\\u03b2 [#3, #4, #24]; its VPS10P domain additionally captures nascent A\\u03b2 and routes it to lysosomes for degradation [#9]. SORLA's itinerary is dictated by its cytoplasmic tail, which engages distinct adaptors\\u2014GGA1/2 via a \\u03c8-\\u03c8-X-X-\\u03c6 motif, the retromer VPS26 subunit via a FANSHY sequence, PACS-1, AP-1/AP-2, and SNX27\\u2014such that retromer-mediated retrograde transport restrains APP processing while GGA-mediated anterograde transport directs A\\u03b2 to lysosomes [#1, #7, #8, #23, #25, #26]. SORLA dimerizes via its 3Fn and VPS10P domains within retromer-positive endosomal tubules to promote APP recycling, and disruption of this dimerization or of receptor maturation by familial missense variants causes ER retention, reduced surface delivery, and increased A\\u03b2 [#32, #44, #45, #48]. Beyond APP, SORLA functions as a general endosomal sorting hub that controls recycling and lysosomal targeting of TrkB, GLUA1, the insulin receptor, and HER2/HER3, and modulates GDNF/GFR\\u03b11, IL-6, and EphA4 signaling, while its shed ectodomain activates EGFR/ERK-dependent neurite outgrowth [#11, #14, #15, #28, #31, #38]. Loss of SORLA\\u2014by knockout, CRISPR haploinsufficiency, or trafficking-defective variants\\u2014consistently produces early-endosome enlargement and endolysosomal and autophagic dysfunction in neurons, a phenotype that places APP, PSEN1, and SORL1 in a common endolysosomal pathway and that can be relieved by lowering APP [#29, #30, #31]. Truncating and missense SORL1 variants are causative for familial Alzheimer's disease through these loss-of-function mechanisms [#9, #32, #45, #48].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Establishing that SORLA is a functional endocytic receptor required showing it matures into a ligand-binding form; furin cleavage of the proreceptor was shown to activate the VPS10P domain for binding of neuropeptides, RAP, ApoE, and lipoprotein lipase.\",\n      \"evidence\": \"Furin cleavage and ligand-binding/endocytosis assays with surface-expression quantification\",\n      \"pmids\": [\"11294867\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not connect receptor activation to a specific physiological cargo in vivo\", \"Cell-surface vs. Golgi pool dynamics not mechanistically resolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"How SORLA tail is read by the sorting machinery was unknown; the cytoplasmic tail was shown to bind GGA1/GGA2 through a novel \\u03c8-\\u03c8-X-X-\\u03c6 motif distinct from sortilin/MPR motifs, defining a basis for Golgi-endosome routing.\",\n      \"evidence\": \"Co-IP with site-directed mutagenesis of C-terminal residues\",\n      \"pmids\": [\"11821067\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence for cargo sorting not yet tested\", \"Single-lab Co-IP without structural detail\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"The link between SORLA and APP was established by showing direct interaction and that SORLA redistributes APP to the Golgi, reducing A\\u03b2, with brain A\\u03b2 elevated in knockout mice\\u2014establishing SORLA as an APP sorting receptor.\",\n      \"evidence\": \"Reciprocal Co-IP, colocalization, neuronal overexpression, SORLA-KO mouse\",\n      \"pmids\": [\"16174740\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Binding interface not mapped\", \"Mechanism of A\\u03b2 reduction (retention vs. degradation) unresolved\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"The molecular basis of SORLA's protective effect was refined by mapping the APP-binding site to the CR-cluster forming a 1:1 complex, and by demonstrating that SORLA reduces BACE1-APP co-residence and BACE-dependent cleavage.\",\n      \"evidence\": \"SPR and analytical ultracentrifugation of recombinant fragments; FRET and APP-shedding assays\",\n      \"pmids\": [\"16489755\", \"16407538\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of stoichiometry not tested\", \"Did not address adaptor-dependent trafficking\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Whether SORLA itself is processed like other amyloid-pathway receptors was addressed by showing TACE shedding followed by \\u03b3-secretase cleavage releases a cytoplasmic domain that translocates to the nucleus and activates transcription.\",\n      \"evidence\": \"\\u03b3-secretase inhibitors, presenilin KO cells, NLS mutagenesis, reporter assays\",\n      \"pmids\": [\"16531402\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcriptional target genes of the released domain not identified\", \"Physiological role of nuclear signaling unknown\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"The trafficking logic was extended by showing SORLA retains APP in the TGN dependent on GGA and PACS-1, and that SORL1 knockdown mis-sorts APP into A\\u03b2-generating compartments, linking expression level to amyloidogenesis and to genetic risk.\",\n      \"evidence\": \"Dominant-negative adaptors, fractionation, A\\u03b2 ELISA, siRNA, genetic association\",\n      \"pmids\": [\"17855360\", \"17220890\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Causality of intronic variants on expression not directly demonstrated\", \"Adaptor hierarchy at distinct trafficking steps not separated\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"The adaptor repertoire controlling SORLA itinerary was defined by identifying the acidic-cluster-dileucine/GGA-binding motifs for Golgi-endosome transport and AP-2 endocytosis, with AP-1 essential for Golgi-endosome cycling and retromer (SNX1/Vps35) for endosomal retrieval.\",\n      \"evidence\": \"Chimeric receptors, AP-1 mu1-deficient cells, Co-IP, trafficking assays\",\n      \"pmids\": [\"17646382\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative flux through each route not measured\", \"Retromer recognition sequence not yet defined\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"The retromer-recognition determinant was identified as a FANSHY sequence bound by VPS26; mutating it redistributes SORLA away from the TGN and mis-sorts APP into amyloidogenic compartments without affecting APP binding, dissociating localization from cargo binding.\",\n      \"evidence\": \"FANSHY mutagenesis, VPS26 knockdown, fractionation, A\\u03b2 ELISA, Co-IP\",\n      \"pmids\": [\"22279231\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not separate retrograde vs. anterograde contributions to A\\u03b2\", \"In vivo confirmation pending at this stage\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Adaptor specificity for the amyloid phenotype was sharpened by showing GGA1 (not GGA2/3) selectively governs LR11 endocytic trafficking and its modulation of APP processing, with BACE1 sorting determinants also implicated.\",\n      \"evidence\": \"Selective siRNA, GGA-site and BACE1 mutagenesis, A\\u03b2 ELISA\",\n      \"pmids\": [\"22621900\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab study\", \"Endogenous-level relevance not tested\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Anterograde vs. retrograde routes were assigned distinct functions in vivo using PACS1-, retromer-, and GGA-binding mutant mice: PACS1/retromer disruption depletes TGN SORLA and enhances APP processing, while GGA disruption raises brain A\\u03b2 via failed anterograde lysosomal A\\u03b2 targeting.\",\n      \"evidence\": \"Transgenic mice with trafficking-mutant SORLA, brain A\\u03b2 and TGN localization assays\",\n      \"pmids\": [\"24001769\", \"23813966\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular machinery of anterograde A\\u03b2 lysosomal delivery incompletely defined\", \"Contribution of SORLA-independent PACS1 effects confounds interpretation\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"A direct A\\u03b2-clearance function was established by showing the VPS10P domain binds nascent A\\u03b2 and routes it to lysosomes; a familial AD mutation impairs this binding, and SORLA overexpression lowers brain A\\u03b2.\",\n      \"evidence\": \"Recombinant VPS10P binding, SORLA-overexpressing mice, lysosomal targeting, mutagenesis\",\n      \"pmids\": [\"24523320\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of A\\u03b2 capture vs. APP retention to net A\\u03b2 lowering unquantified\", \"Structural basis of VPS10P\\u2013A\\u03b2 binding unresolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"The two trafficking routes were definitively separated in vivo and the CR-cluster mechanism refined: retromer disruption enhances APP processing whereas GGA disruption raises A\\u03b2 through anterograde defects, and CR-domain integrity controls APP O-glycosylation that gates amyloidogenic processing.\",\n      \"evidence\": \"Trafficking-mutant transgenic mice; CR-deletion/mutant cell lines, glycosylation analysis, A\\u03b2/sAPP ELISA\",\n      \"pmids\": [\"26377460\", \"25525276\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How glycosylation alters secretase access not mechanistically detailed\", \"Single-lab glycosylation findings\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"SORLA's role as a general recycling receptor was extended by showing SNX27 forms a ternary complex with SORLA and APP that drives APP endosome-to-surface recycling and favors non-amyloidogenic cleavage in a SORLA-dependent manner.\",\n      \"evidence\": \"Co-IP, SNX27/SORLA double knockdown, APP recycling kinetics, surface cleavage products\",\n      \"pmids\": [\"27466343\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab Co-IP\", \"Structural basis of SNX27 tail recognition not defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Whether SORL1 loss causes amyloid-independent organelle pathology was tested in isogenic hiPSC neurons: SORL1 depletion enlarges early endosomes and mis-localizes APP, and BACE inhibition fails to rescue endosome enlargement, demonstrating an APP-processing-independent endosomal defect that is neuron-specific.\",\n      \"evidence\": \"CRISPR SORL1 KO hiPSCs, endosome quantification, BACE inhibitor epistasis, neuron vs. microglia comparison\",\n      \"pmids\": [\"32492427\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cargo whose mis-trafficking drives enlargement not identified here\", \"Mechanism of neuronal specificity unexplained\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Gene-dosage and pathway placement were established by an isogenic WT/het/null series showing haploinsufficiency enlarges endosomes while complete loss adds lysosomal and autophagy defects, all relieved by APP-lowering ASO\\u2014placing PSEN1, APP, and SORL1 in one endolysosomal pathway.\",\n      \"evidence\": \"CRISPR truncation series in hiPSC neurons, endolysosomal/autophagy assays, APP ASO rescue\",\n      \"pmids\": [\"34133918\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why APP lowering rescues despite APP-independent endosome phenotype reported earlier remains to be reconciled\", \"Lysosomal step affected not pinpointed\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"The loss-of-function mechanism of disease variants was defined by showing rare missense variants (R332W, S577P, R654W) impair receptor maturation and cause ER retention with increased A\\u03b2 at endogenous expression levels.\",\n      \"evidence\": \"Large variant screen in HEK293, CRISPR hiPSCs, ER retention and PM delivery assays, A\\u03b2 ELISA\",\n      \"pmids\": [\"34922638\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of misfolding per variant not fully resolved\", \"Whether all variants act solely via ER retention untested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"The cargo spectrum and synaptic consequences of SORL1 loss were broadened by showing impaired endosomal trafficking of GLUA1, TRKB, and APP with reduced surface recycling and diminished synaptic activity, reversible by increased SORL1.\",\n      \"evidence\": \"Isogenic hiPSC neurons with depletion/overexpression, trafficking and recycling assays, MEA, RNA-seq\",\n      \"pmids\": [\"35226190\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct binding of SORLA to each cargo tail not all mapped\", \"Link between specific cargo and synaptic deficit not isolated\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"The structural basis of SORLA function was advanced by crystallography showing dimerization via 3Fn and VPS10P domains in retromer-positive tubules, where a 3Fn-transmembrane-cytoplasmic fragment enhances retromer-dependent APP recycling and reduces A\\u03b2.\",\n      \"evidence\": \"X-ray crystallography, AI modeling, domain-fragment dimerization and APP recycling assays\",\n      \"pmids\": [\"36652482\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length receptor dimer architecture not resolved\", \"Regulation of dimerization in cells unclear\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Dimerization was shown to be functionally essential and disease-relevant: the familial p.Y1816C variant impairs endosomal homodimerization, reducing surface trafficking and ectodomain shedding and enlarging endosomes, with rescue by the 3Fn-minireceptor.\",\n      \"evidence\": \"Family segregation, CRISPR hiPSC neurons, dimerization/trafficking/shedding assays, minireceptor rescue\",\n      \"pmids\": [\"39226352\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether dimerization defect alone accounts for full neuronal phenotype untested\", \"Therapeutic feasibility of minireceptor rescue in vivo unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"An additional disease-variant mechanism was characterized by showing the familial p.R953C YWTD-domain variant causes ER retention with decreased maturation, shedding, and endosomal trafficking, reinforcing maturation defects as a recurrent loss-of-function route.\",\n      \"evidence\": \"Family segregation, ER retention, maturation/shedding, endosomal trafficking assays\",\n      \"pmids\": [\"38244079\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab characterization\", \"Structural consequence within YWTD domain not resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How SORLA's diverse cargo-sorting roles (APP, TrkB, GLUA1, insulin receptor, HER2/3) are coordinated, prioritized, and regulated within a single receptor remains unresolved, as does the structural basis of full-length receptor dimerization and the precise lysosomal step disrupted by complete loss.\",\n      \"evidence\": \"No single study integrates the multi-cargo sorting logic\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No unified model of cargo selectivity\", \"Full-length structure and regulated dimerization undefined\", \"Tissue-specific cargo priorities unmapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0038024\", \"supporting_discovery_ids\": [0, 6, 9, 11, 15, 28]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [1, 8, 23, 26]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [3, 27, 39]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [6, 12, 19]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [0, 2, 3, 6]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [0, 1, 8, 29, 44]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [6, 18, 26, 32]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [9, 11, 12, 30]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [17]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-9609507\", \"supporting_discovery_ids\": [0, 1, 8, 25, 26, 31]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [1, 6, 28, 46]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [9, 30, 32, 45, 47, 48]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [11, 27, 38, 39, 46]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [30]}\n    ],\n    \"complexes\": [\"retromer (VPS26-associated)\", \"SORLA-APP complex\", \"SORLA-HER2-HER3 trimeric complex\"],\n    \"partners\": [\"APP\", \"BACE1\", \"GGA1\", \"VPS26\", \"PACS1\", \"SNX27\", \"HER2\", \"EphA4\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}